{ "instance": { "rnaz-20220930xs1.htm": { "axisCustom": 0, "axisStandard": 21, "baseTaxonomies": { "http://fasb.org/us-gaap/2021-01-31": 832, "http://xbrl.sec.gov/dei/2021q4": 8 }, "contextCount": 261, "dts": { "calculationLink": { "local": [ "rnaz-20220930_cal.xml" ] }, "definitionLink": { "local": [ "rnaz-20220930_def.xml" ] }, "inline": { "local": [ "rnaz-20220930xs1.htm" ] }, "labelLink": { "local": [ "rnaz-20220930_lab.xml" ] }, "presentationLink": { "local": [ "rnaz-20220930_pre.xml" ] }, "schema": { "local": [ "rnaz-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 522, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 43, "http://www.transcodetherapeutics.com/20220930": 3, "http://xbrl.sec.gov/dei/2021q4": 2, "total": 48 }, "keyCustom": 115, "keyStandard": 223, "memberCustom": 26, "memberStandard": 26, "nsprefix": "rnaz", "nsuri": "http://www.transcodetherapeutics.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100090 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.transcodetherapeutics.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "110401 - Disclosure - Prepaid Expenses and Other Current Assets", "menuCat": "Notes", "order": "10", "role": "http://www.transcodetherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets", "shortName": "Prepaid Expenses and Other Current Assets", "subGroupType": "", "uniqueAnchor": null }, "R100": { "firstAnchor": { "ancestors": [ "p", "rnaz:DeferredGrantIncomeDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_4_30_2021_UVo05WJhO0yjJEzoPxSPfw", "decimals": "0", "first": true, "lang": null, "name": "rnaz:AggregateGrantReceivableEstimatedAmount", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240701 - Disclosure - Deferred Grant Income (Details)", "menuCat": "Details", "order": "100", "role": "http://www.transcodetherapeutics.com/role/DisclosureDeferredGrantIncomeDetailss", "shortName": "Deferred Grant Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "rnaz:DeferredGrantIncomeDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": "0", "lang": null, "name": "rnaz:GrantIncomeReceivable", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_12_31_2021_6JKcIZ7TkU672UGM8l3-NA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240801 - Disclosure - Commitments and Contingencies (Details)", "menuCat": "Details", "order": "101", "role": "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_rnaz_MassachusettsBiomedicalInitiativesInc.Member_gyf0BflveUipzDUWR1zwnw", "decimals": "0", "lang": null, "name": "rnaz:AdditionalSubleasePayment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_11_1_2018_To_11_30_2018_dRzZqFsKRkyKE_4Pjnn8Fg", "decimals": "0", "first": true, "lang": null, "name": "rnaz:OneTimeNonRefundableFeeOfLicenseAgreement", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240802 - Disclosure - Commitments and Contingencies - License Agreement (Details)", "menuCat": "Details", "order": "102", "role": "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss", "shortName": "Commitments and Contingencies - License Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_9_30_2022_p44Q5s_h502JVvigcbN3Lw", "decimals": "0", "lang": null, "name": "rnaz:AccruedLicenseObligations", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_7_29_2022_To_7_29_2022_srt_CounterpartyNameAxis_rnaz_UniversityOfTexasM.D.AndersonCancerCenterMdAndersonMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_iOPCzIpxSEm442cZ0xoS1g", "decimals": null, "first": true, "lang": "en-US", "name": "rnaz:StrategicCollaborationAgreementTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240803 - Disclosure - Commitments and Contingencies - Collaboration Agreement and Litigation (Details)", "menuCat": "Details", "order": "103", "role": "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementAndLitigationDetails", "shortName": "Commitments and Contingencies - Collaboration Agreement and Litigation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_7_29_2022_To_7_29_2022_srt_CounterpartyNameAxis_rnaz_UniversityOfTexasM.D.AndersonCancerCenterMdAndersonMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_iOPCzIpxSEm442cZ0xoS1g", "decimals": null, "first": true, "lang": "en-US", "name": "rnaz:StrategicCollaborationAgreementTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R104": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_4_27_2021_9CUQYv3PDEKQp_GMgGcTWw", "decimals": "INF", "first": true, "lang": null, "name": "rnaz:MaximumNumberOfSharesWhichCompanyIsAuthorizedToIssue", "reportCount": 1, "unitRef": "Unit_Standard_shares_IPjECNbZHUOfBf0bPDT3KQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240901 - Disclosure - Stockholders' Equity (Details)", "menuCat": "Details", "order": "104", "role": "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss", "shortName": "Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": "INF", "lang": null, "name": "rnaz:CommonStockVotingRightsPerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_iTBxdMk_s0a_Ip78rxHGww", "xsiNil": "false" } }, "R105": { "firstAnchor": { "ancestors": [ "p", "rnaz:WarrantDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_9_30_2022_p44Q5s_h502JVvigcbN3Lw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "Unit_Standard_shares_IPjECNbZHUOfBf0bPDT3KQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241001 - Disclosure - Warrants (Details)", "menuCat": "Details", "order": "105", "role": "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetailss", "shortName": "Warrants (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R106": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_WPzLd0lYAUekA-NIk4gXvA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241101 - Disclosure - Share-Based Compensation (Details)", "menuCat": "Details", "order": "106", "role": "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationDetailss", "shortName": "Share-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R107": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_9_1_2022_To_9_30_2022_d2K1L4G-CkmCWYXY77g7Fw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unitRef": "Unit_Standard_shares_IPjECNbZHUOfBf0bPDT3KQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241102 - Disclosure - Share-Based Compensation - Additional Information (Details)", "menuCat": "Details", "order": "107", "role": "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss", "shortName": "Share-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_us-gaap_PlanNameAxis_rnaz_StockOptionAndIncentivePlan2021Member_TSD9uWRNC0yy190kSf_m8w", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_IPjECNbZHUOfBf0bPDT3KQ", "xsiNil": "false" } }, "R108": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_12_31_2021_6JKcIZ7TkU672UGM8l3-NA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_IPjECNbZHUOfBf0bPDT3KQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241103 - Disclosure - Share-Based Compensation - Information About Options to Purchase Common Stock (Details)", "menuCat": "Details", "order": "108", "role": "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetailss", "shortName": "Share-Based Compensation - Information About Options to Purchase Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R109": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9OntsIJVC0-9xXXcgVUZIg", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unitRef": "Unit_Standard_pure_MZZJyOBWrEKHwAxmLr_wsg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241104 - Disclosure - Share-Based Compensation - Grant-date Fair Value of Options Granted (Details)", "menuCat": "Details", "order": "109", "role": "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetailss", "shortName": "Share-Based Compensation - Grant-date Fair Value of Options Granted (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "110501 - Disclosure - Property and Equipment", "menuCat": "Notes", "order": "11", "role": "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": null }, "R110": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_Iv0-dccHTEGu0vfj9Rlneg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241105 - Disclosure - Share-Based Compensation - Stock-based Compensation Expense (Details)", "menuCat": "Details", "order": "110", "role": "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationStockBasedCompensationExpenseDetailss", "shortName": "Share-Based Compensation - Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R111": { "firstAnchor": { "ancestors": [ "p", "rnaz:EmployeeStockPurchasePlanTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_Iv0-dccHTEGu0vfj9Rlneg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_IPjECNbZHUOfBf0bPDT3KQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241201 - Disclosure - Employee Stock Purchase Plan (Details)", "menuCat": "Details", "order": "111", "role": "http://www.transcodetherapeutics.com/role/DisclosureEmployeeStockPurchasePlanDetails", "shortName": "Employee Stock Purchase Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "rnaz:EmployeeStockPurchasePlanTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_Iv0-dccHTEGu0vfj9Rlneg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_IPjECNbZHUOfBf0bPDT3KQ", "xsiNil": "false" } }, "R112": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_LjOxBsq0x0S0xOkIvzPMTA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241301 - Disclosure - Net Loss Per Share - Schedule of Computation of Basic And Diluted Net Earnings (Loss) Per Share (Details)", "menuCat": "Details", "order": "112", "role": "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetEarningsLossPerShareDetails", "shortName": "Net Loss Per Share - Schedule of Computation of Basic And Diluted Net Earnings (Loss) Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_LjOxBsq0x0S0xOkIvzPMTA", "decimals": "0", "lang": null, "name": "rnaz:WeightedAverageCommonSharesOutstandingAntiDiluted", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_IPjECNbZHUOfBf0bPDT3KQ", "xsiNil": "false" } }, "R113": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_LjOxBsq0x0S0xOkIvzPMTA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_IPjECNbZHUOfBf0bPDT3KQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241302 - Disclosure - Net Loss Per Share - Computation of diluted earnings (loss) per weighted-average share outstanding (Details)", "menuCat": "Details", "order": "113", "role": "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShareComputationOfDilutedEarningsLossPerWeightedAverageShareOutstandingDetails", "shortName": "Net Loss Per Share - Computation of diluted earnings (loss) per weighted-average share outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_LjOxBsq0x0S0xOkIvzPMTA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_IPjECNbZHUOfBf0bPDT3KQ", "xsiNil": "false" } }, "R114": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxExpenseBenefit", "us-gaap:IncomeTaxExpenseBenefit", "us-gaap:IncomeTaxExpenseBenefit", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_LjOxBsq0x0S0xOkIvzPMTA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241401 - Disclosure - Income Taxes (Details)", "menuCat": "Details", "order": "114", "role": "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R115": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_12_31_2020_eMEgWmIN8E-fIpKB_YKkWw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241501 - Disclosure - Related -Party Transactions (Details)", "menuCat": "Details", "order": "115", "role": "http://www.transcodetherapeutics.com/role/DisclosureRelatedPartyTransactionsDetailss", "shortName": "Related -Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "110601 - Disclosure - Accounts Payable and Accrued Expenses", "menuCat": "Notes", "order": "12", "role": "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpenses", "shortName": "Accounts Payable and Accrued Expenses", "subGroupType": "", "uniqueAnchor": null }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "rnaz:DeferredGrantIncomeDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "110701 - Disclosure - Deferred Grant Income", "menuCat": "Notes", "order": "13", "role": "http://www.transcodetherapeutics.com/role/DisclosureDeferredGrantIncome", "shortName": "Deferred Grant Income", "subGroupType": "", "uniqueAnchor": null }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "110801 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "14", "role": "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": null }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_Iv0-dccHTEGu0vfj9Rlneg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "110901 - Disclosure - Convertible Promissory Notes", "menuCat": "Notes", "order": "15", "role": "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotes", "shortName": "Convertible Promissory Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_Iv0-dccHTEGu0vfj9Rlneg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "111001 - Disclosure - Stockholders' Equity", "menuCat": "Notes", "order": "16", "role": "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": null }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "rnaz:WarrantDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "111101 - Disclosure - Warrants", "menuCat": "Notes", "order": "17", "role": "http://www.transcodetherapeutics.com/role/DisclosureWarrants", "shortName": "Warrants", "subGroupType": "", "uniqueAnchor": null }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "111201 - Disclosure - Share-Based Compensation", "menuCat": "Notes", "order": "18", "role": "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": null }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "111301 - Disclosure - Net Loss Per Share", "menuCat": "Notes", "order": "19", "role": "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": null }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_12_31_2020_eMEgWmIN8E-fIpKB_YKkWw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100100 - Statement - BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "shortName": "BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_12_31_2020_eMEgWmIN8E-fIpKB_YKkWw", "decimals": "0", "lang": null, "name": "us-gaap:AssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "111401 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "20", "role": "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": null }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "111501 - Disclosure - Related -Party Transactions", "menuCat": "Notes", "order": "21", "role": "http://www.transcodetherapeutics.com/role/DisclosureRelatedPartyTransactions", "shortName": "Related -Party Transactions", "subGroupType": "", "uniqueAnchor": null }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_Iv0-dccHTEGu0vfj9Rlneg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "111601 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "22", "role": "http://www.transcodetherapeutics.com/role/DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_Iv0-dccHTEGu0vfj9Rlneg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "120202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "23", "role": "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": null }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "rnaz:PropertyPlantAndEquipmentSEstimatedUsefulLifePolicyTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "130203 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_Iv0-dccHTEGu0vfj9Rlneg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "130303 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_Iv0-dccHTEGu0vfj9Rlneg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "rnaz:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "130403 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.transcodetherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "130503 - Disclosure - Property and Equipment (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "130603 - Disclosure - Accounts Payable and Accrued Expenses (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesTables", "shortName": "Accounts Payable and Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "rnaz:ScheduleOfMilestonePaymentsCompanyShallPayToLicensorTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "130803 - Disclosure - Commitments and Contingencies (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_9_30_2022_p44Q5s_h502JVvigcbN3Lw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_iTBxdMk_s0a_Ip78rxHGww", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100105 - Statement - BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.transcodetherapeutics.com/role/StatementBalanceSheetsParenthetical", "shortName": "BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_Iv0-dccHTEGu0vfj9Rlneg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "130903 - Disclosure - Convertible Promissory Notes (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesTables", "shortName": "Convertible Promissory Notes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_Iv0-dccHTEGu0vfj9Rlneg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_Iv0-dccHTEGu0vfj9Rlneg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "131003 - Disclosure - Stockholders Equity (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityTables", "shortName": "Stockholders Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_Iv0-dccHTEGu0vfj9Rlneg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_Iv0-dccHTEGu0vfj9Rlneg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "131103 - Disclosure - Warrants (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.transcodetherapeutics.com/role/DisclosureWarrantsTables", "shortName": "Warrants (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "131203 - Disclosure - Share-Based Compensation (Table)", "menuCat": "Tables", "order": "33", "role": "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationTable", "shortName": "Share-Based Compensation (Table)", "subGroupType": "tables", "uniqueAnchor": null }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "131303 - Disclosure - Net Loss Per Share (Tables)", "menuCat": "Tables", "order": "34", "role": "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_Iv0-dccHTEGu0vfj9Rlneg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "131403 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "35", "role": "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_Iv0-dccHTEGu0vfj9Rlneg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_EfkVXtdIKkO8bbIKRuf14Q", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140101 - Disclosure - Nature of Business and Liquidity (Details)", "menuCat": "Details", "order": "36", "role": "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "shortName": "Nature of Business and Liquidity (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_9_30_2022_p44Q5s_h502JVvigcbN3Lw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140201 - Disclosure - Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details)", "menuCat": "Details", "order": "37", "role": "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails", "shortName": "Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_9_30_2022_p44Q5s_h502JVvigcbN3Lw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140202 - Disclosure - Summary of Significant Accounting Policies - Research and Development (Details)", "menuCat": "Details", "order": "38", "role": "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentDetails", "shortName": "Summary of Significant Accounting Policies - Research and Development (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ResearchAndDevelopmentExpensePolicy", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_12_31_2021_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_us-gaap_ResearchAndDevelopmentArrangementMember_lCD-QtjCwECGrPiZET3E8A", "decimals": "0", "lang": null, "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "rnaz:PropertyPlantAndEquipmentSEstimatedUsefulLifePolicyTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_rnaz_LaboratoryEquipmentMember_0mogmlyVCked6pCMdSiaBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140203 - Disclosure - Summary of Significant Accounting Policies - Schedule Of Property Plant And Equipment Table (Details)", "menuCat": "Details", "order": "39", "role": "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyPlantAndEquipmentTableDetails", "shortName": "Summary of Significant Accounting Policies - Schedule Of Property Plant And Equipment Table (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_Iv0-dccHTEGu0vfj9Rlneg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100200 - Statement - STATEMENTS OF OPERATIONS", "menuCat": "Statements", "order": "4", "role": "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations", "shortName": "STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_Iv0-dccHTEGu0vfj9Rlneg", "decimals": "0", "lang": null, "name": "us-gaap:GainLossOnDispositionOfAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_9_30_2022_p44Q5s_h502JVvigcbN3Lw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredCosts", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140204 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "menuCat": "Details", "order": "40", "role": "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_12_31_2020_eMEgWmIN8E-fIpKB_YKkWw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140301 - Disclosure - Fair Value Measurements (Details)", "menuCat": "Details", "order": "41", "role": "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_12_31_2020_eMEgWmIN8E-fIpKB_YKkWw", "decimals": "0", "lang": null, "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_EfkVXtdIKkO8bbIKRuf14Q", "decimals": "0", "first": true, "lang": null, "name": "rnaz:ChangesInFairValueOfDerivativeLiability", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140302 - Disclosure - Fair Value Measurements - Changes in the Fair Value of Level 3 Financial Instruments (Details)", "menuCat": "Details", "order": "42", "role": "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3FinancialInstrumentsDetails", "shortName": "Fair Value Measurements - Changes in the Fair Value of Level 3 Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_C_eWI_MLHkS3CMLFFpZ6lQ", "decimals": "0", "lang": null, "name": "rnaz:ChangesInFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "rnaz:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_9_30_2022_p44Q5s_h502JVvigcbN3Lw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherPrepaidExpenseCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140401 - Disclosure - Prepaid Expenses and Other Current Assets (Details)", "menuCat": "Details", "order": "43", "role": "http://www.transcodetherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "shortName": "Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_9_30_2022_p44Q5s_h502JVvigcbN3Lw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140501 - Disclosure - Property and Equipment (Details)", "menuCat": "Details", "order": "44", "role": "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipmentDetails", "shortName": "Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_rnaz_LaboratoryEquipmentMember_WRcYnqS470Gs5wwAr6X_wg", "decimals": "0", "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_12_31_2021_6JKcIZ7TkU672UGM8l3-NA", "decimals": "0", "first": true, "lang": null, "name": "rnaz:AccruedProfessionalFeesPayable", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140601 - Disclosure - Accounts Payable and Accrued Expenses (Details)", "menuCat": "Details", "order": "45", "role": "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails", "shortName": "Accounts Payable and Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_12_31_2021_6JKcIZ7TkU672UGM8l3-NA", "decimals": "0", "first": true, "lang": null, "name": "rnaz:AccruedProfessionalFeesPayable", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "rnaz:DeferredGrantIncomeDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_4_30_2021_UVo05WJhO0yjJEzoPxSPfw", "decimals": "0", "first": true, "lang": null, "name": "rnaz:AggregateGrantReceivableEstimatedAmount", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140701 - Disclosure - Deferred Grant Income (Details)", "menuCat": "Details", "order": "46", "role": "http://www.transcodetherapeutics.com/role/DisclosureDeferredGrantIncomeDetails", "shortName": "Deferred Grant Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_12_31_2021_6JKcIZ7TkU672UGM8l3-NA", "decimals": "0", "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_12_31_2021_6JKcIZ7TkU672UGM8l3-NA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140801 - Disclosure - Commitments and Contingencies (Details)", "menuCat": "Details", "order": "47", "role": "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R48": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_11_1_2018_To_11_30_2018_dRzZqFsKRkyKE_4Pjnn8Fg", "decimals": "0", "first": true, "lang": null, "name": "rnaz:OneTimeNonRefundableFeeOfLicenseAgreement", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140802 - Disclosure - Commitments and Contingencies - License Agreement (Details)", "menuCat": "Details", "order": "48", "role": "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "shortName": "Commitments and Contingencies - License Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_12_31_2021_6JKcIZ7TkU672UGM8l3-NA", "decimals": "0", "lang": null, "name": "rnaz:AccountsPayableAndAccruedExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_5_1_2018_To_5_31_2020_T2vFv_55LU-xmK_QopspmA", "decimals": "INF", "first": true, "lang": null, "name": "rnaz:NumberOfConvertiblePromissoryNotes", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_fIZvxRaxPUujKu7axLL6Ng", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "140901 - Disclosure - Convertible Promissory Notes (Details)", "menuCat": "Details", "order": "49", "role": "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails", "shortName": "Convertible Promissory Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_5_1_2018_To_5_31_2020_T2vFv_55LU-xmK_QopspmA", "decimals": "INF", "first": true, "lang": null, "name": "rnaz:NumberOfConvertiblePromissoryNotes", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_fIZvxRaxPUujKu7axLL6Ng", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yRa92AWDbU6c0OrpsrDuJw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100300 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)", "menuCat": "Statements", "order": "5", "role": "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficit", "shortName": "STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YVwTZ_JOC02vmm-AHSj4gg", "decimals": "0", "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_4_27_2021_9CUQYv3PDEKQp_GMgGcTWw", "decimals": "INF", "first": true, "lang": null, "name": "rnaz:MaximumNumberOfSharesWhichCompanyIsAuthorizedToIssue", "reportCount": 1, "unitRef": "Unit_Standard_shares_IPjECNbZHUOfBf0bPDT3KQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141001 - Disclosure - Stockholders Equity (Details)", "menuCat": "Details", "order": "50", "role": "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "shortName": "Stockholders Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_6B_I7xMYd0-v_xJeorAnjQ", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_IPjECNbZHUOfBf0bPDT3KQ", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_12_31_2021_6JKcIZ7TkU672UGM8l3-NA", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_iTBxdMk_s0a_Ip78rxHGww", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141101 - Disclosure - Warrants (Details)", "menuCat": "Details", "order": "51", "role": "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetails", "shortName": "Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "rnaz:WarrantDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_5_2_2018_To_5_2_2018_us-gaap_DebtInstrumentAxis_rnaz_NoteOneMember_pgojlEHvWUCgw0SGUc8erw", "decimals": "0", "lang": null, "name": "rnaz:NumberOfSharesOfCommonStockSubjectToWarrantsAsPercentToNumberOfSharesOfCommonStockIntoWhichNoteOneConverts", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_MZZJyOBWrEKHwAxmLr_wsg", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_12_31_2020_eMEgWmIN8E-fIpKB_YKkWw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141102 - Disclosure - Warrants - Schedule of Assumptions of the Fair Value of Warrant Liability (Details)", "menuCat": "Details", "order": "52", "role": "http://www.transcodetherapeutics.com/role/DisclosureWarrantsScheduleOfAssumptionsOfFairValueOfWarrantLiabilityDetails", "shortName": "Warrants - Schedule of Assumptions of the Fair Value of Warrant Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "rnaz:WarrantDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_7_13_2021_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_OMv_DgkniEuRpA5MejoU4Q", "decimals": "0", "lang": null, "name": "us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_WPzLd0lYAUekA-NIk4gXvA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141201 - Disclosure - Share-Based Compensation (Details)", "menuCat": "Details", "order": "53", "role": "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationDetails", "shortName": "Share-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "Unit_Standard_shares_IPjECNbZHUOfBf0bPDT3KQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141202 - Disclosure - Share-Based Compensation - Additional Information (Details)", "menuCat": "Details", "order": "54", "role": "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "shortName": "Share-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_12_31_2021_6JKcIZ7TkU672UGM8l3-NA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_IPjECNbZHUOfBf0bPDT3KQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141203 - Disclosure - Share-Based Compensation - Information About Options to Purchase Common Stock (Details)", "menuCat": "Details", "order": "55", "role": "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetails", "shortName": "Share-Based Compensation - Information About Options to Purchase Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R56": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9OntsIJVC0-9xXXcgVUZIg", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unitRef": "Unit_Standard_pure_MZZJyOBWrEKHwAxmLr_wsg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141204 - Disclosure - Share-Based Compensation - Grant-date Fair Value of Options Granted (Details)", "menuCat": "Details", "order": "56", "role": "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetails", "shortName": "Share-Based Compensation - Grant-date Fair Value of Options Granted (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R57": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_Iv0-dccHTEGu0vfj9Rlneg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141205 - Disclosure - Share-Based Compensation - Stock-based Compensation Expense (Details)", "menuCat": "Details", "order": "57", "role": "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationStockBasedCompensationExpenseDetails", "shortName": "Share-Based Compensation - Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R58": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_LjOxBsq0x0S0xOkIvzPMTA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141301 - Disclosure - Net Loss Per Share (Details)", "menuCat": "Details", "order": "58", "role": "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShareDetails", "shortName": "Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R59": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_Iv0-dccHTEGu0vfj9Rlneg", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_MZZJyOBWrEKHwAxmLr_wsg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141401 - Disclosure - Income Taxes - Effective income tax rate reconciliation (Details)", "menuCat": "Details", "order": "59", "role": "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails", "shortName": "Income Taxes - Effective income tax rate reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_Iv0-dccHTEGu0vfj9Rlneg", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_MZZJyOBWrEKHwAxmLr_wsg", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_Iv0-dccHTEGu0vfj9Rlneg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100400 - Statement - STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "6", "role": "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "shortName": "STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_Iv0-dccHTEGu0vfj9Rlneg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_12_31_2021_6JKcIZ7TkU672UGM8l3-NA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141402 - Disclosure - Income Taxes - Deferred tax assets (Details)", "menuCat": "Details", "order": "60", "role": "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails", "shortName": "Income Taxes - Deferred tax assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_12_31_2021_6JKcIZ7TkU672UGM8l3-NA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxExpenseBenefit", "us-gaap:IncomeTaxExpenseBenefit", "us-gaap:IncomeTaxExpenseBenefit", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_LjOxBsq0x0S0xOkIvzPMTA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141403 - Disclosure - Income Taxes - Additional information (Details)", "menuCat": "Details", "order": "61", "role": "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_Iv0-dccHTEGu0vfj9Rlneg", "decimals": "0", "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_12_31_2020_eMEgWmIN8E-fIpKB_YKkWw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141501 - Disclosure - Related -Party Transactions (Details)", "menuCat": "Details", "order": "62", "role": "http://www.transcodetherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "shortName": "Related -Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R63": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_12_31_2021_6JKcIZ7TkU672UGM8l3-NA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "141601 - Disclosure - Subsequent Events (Details)", "menuCat": "Details", "order": "63", "role": "http://www.transcodetherapeutics.com/role/DisclosureSubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_3_1_2022_To_3_1_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_K3HtyN4YmEmWqbFZmeLxxw", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_IPjECNbZHUOfBf0bPDT3KQ", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_9_30_2022_p44Q5s_h502JVvigcbN3Lw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "200100 - Statement - BALANCE SHEETS", "menuCat": "Uncategorized", "order": "64", "role": "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss", "shortName": "BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_9_30_2022_p44Q5s_h502JVvigcbN3Lw", "decimals": "0", "lang": null, "name": "us-gaap:GrantsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_9_30_2022_p44Q5s_h502JVvigcbN3Lw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_iTBxdMk_s0a_Ip78rxHGww", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "200105 - Statement - BALANCE SHEETS (Parenthetical)", "menuCat": "Cover", "order": "65", "role": "http://www.transcodetherapeutics.com/role/StatementBalanceSheetsParentheticals", "shortName": "BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R66": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_LjOxBsq0x0S0xOkIvzPMTA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "200200 - Statement - STATEMENTS OF OPERATIONS", "menuCat": "Statements", "order": "66", "role": "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperationss", "shortName": "STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_LjOxBsq0x0S0xOkIvzPMTA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yRa92AWDbU6c0OrpsrDuJw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "200300 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)", "menuCat": "Statements", "order": "67", "role": "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits", "shortName": "STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_L8wxVUIMYECJpjj1yK7pfA", "decimals": "0", "lang": null, "name": "rnaz:ProceedsFromSubscriptionReceivableSource2", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "200400 - Statement - STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "68", "role": "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss", "shortName": "STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210101 - Disclosure - Nature of Business and Liquidity", "menuCat": "Notes", "order": "69", "role": "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquiditys", "shortName": "Nature of Business and Liquidity", "subGroupType": "", "uniqueAnchor": null }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "110101 - Disclosure - Nature of Business and Liquidity", "menuCat": "Notes", "order": "7", "role": "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidity", "shortName": "Nature of Business and Liquidity", "subGroupType": "", "uniqueAnchor": null }, "R70": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210201 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "70", "role": "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciess", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": null }, "R71": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210301 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "71", "role": "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementss", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": null }, "R72": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210401 - Disclosure - Prepaid Expenses and Other Current Assets", "menuCat": "Notes", "order": "72", "role": "http://www.transcodetherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetss", "shortName": "Prepaid Expenses and Other Current Assets", "subGroupType": "", "uniqueAnchor": null }, "R73": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210501 - Disclosure - Property and Equipment", "menuCat": "Notes", "order": "73", "role": "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipments", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": null }, "R74": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210601 - Disclosure - Accounts Payable and Accrued Expenses", "menuCat": "Notes", "order": "74", "role": "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensess", "shortName": "Accounts Payable and Accrued Expenses", "subGroupType": "", "uniqueAnchor": null }, "R75": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "rnaz:DeferredGrantIncomeDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210701 - Disclosure - Grant Income", "menuCat": "Notes", "order": "75", "role": "http://www.transcodetherapeutics.com/role/DisclosureGrantIncome", "shortName": "Grant Income", "subGroupType": "", "uniqueAnchor": null }, "R76": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210801 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "76", "role": "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciess", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": null }, "R77": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210901 - Disclosure - Stockholders' Equity", "menuCat": "Notes", "order": "77", "role": "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquitys", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": null }, "R78": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "rnaz:WarrantDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211001 - Disclosure - Warrants", "menuCat": "Notes", "order": "78", "role": "http://www.transcodetherapeutics.com/role/DisclosureWarrantss", "shortName": "Warrants", "subGroupType": "", "uniqueAnchor": null }, "R79": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211101 - Disclosure - Share-Based Compensation", "menuCat": "Notes", "order": "79", "role": "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensations", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "110201 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "8", "role": "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": null }, "R80": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "rnaz:EmployeeStockPurchasePlanTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211201 - Disclosure - Employee Stock Purchase Plan", "menuCat": "Notes", "order": "80", "role": "http://www.transcodetherapeutics.com/role/DisclosureEmployeeStockPurchasePlan", "shortName": "Employee Stock Purchase Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "rnaz:EmployeeStockPurchasePlanTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211301 - Disclosure - Net Loss Per Share", "menuCat": "Notes", "order": "81", "role": "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShares", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": null }, "R82": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211401 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "82", "role": "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxess", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": null }, "R83": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211501 - Disclosure - Related -Party Transactions", "menuCat": "Notes", "order": "83", "role": "http://www.transcodetherapeutics.com/role/DisclosureRelatedPartyTransactionss", "shortName": "Related -Party Transactions", "subGroupType": "", "uniqueAnchor": null }, "R84": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "220202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "84", "role": "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": null }, "R85": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "rnaz:PropertyPlantAndEquipmentSEstimatedUsefulLifePolicyTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230203 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "85", "role": "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTabless", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R86": { "firstAnchor": { "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "rnaz:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230403 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "menuCat": "Tables", "order": "86", "role": "http://www.transcodetherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTabless", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R87": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230503 - Disclosure - Property and Equipment (Tables)", "menuCat": "Tables", "order": "87", "role": "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipmentTabless", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R88": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230603 - Disclosure - Accounts Payable and Accrued Expenses (Tables)", "menuCat": "Tables", "order": "88", "role": "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesTabless", "shortName": "Accounts Payable and Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R89": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "rnaz:ScheduleOfMilestonePaymentsCompanyShallPayToLicensorTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230803 - Disclosure - Commitments and Contingencies (Tables)", "menuCat": "Tables", "order": "89", "role": "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesTabless", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "110301 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "9", "role": "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": null }, "R90": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_Iv0-dccHTEGu0vfj9Rlneg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "231003 - Disclosure - Warrants (Tables)", "menuCat": "Tables", "order": "90", "role": "http://www.transcodetherapeutics.com/role/DisclosureWarrantsTabless", "shortName": "Warrants (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R91": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "231103 - Disclosure - Share-Based Compensation (Table)", "menuCat": "Tables", "order": "91", "role": "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationTables", "shortName": "Share-Based Compensation (Table)", "subGroupType": "tables", "uniqueAnchor": null }, "R92": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "231303 - Disclosure - Net Loss Per Share (Tables)", "menuCat": "Tables", "order": "92", "role": "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShareTabless", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": null, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021_EfkVXtdIKkO8bbIKRuf14Q", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240101 - Disclosure - Nature of Business and Liquidity - IPO (Details)", "menuCat": "Details", "order": "93", "role": "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityIpoDetails", "shortName": "Nature of Business and Liquidity - IPO (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R94": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_s4oevmPAf0CduYZey79HVg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240102 - Disclosure - Nature of Business and Liquidity - Additional Information (Details)", "menuCat": "Details", "order": "94", "role": "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityAdditionalInformationDetails", "shortName": "Nature of Business and Liquidity - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R95": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "rnaz:PropertyPlantAndEquipmentSEstimatedUsefulLifePolicyTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_rnaz_LaboratoryEquipmentMember_0mogmlyVCked6pCMdSiaBQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240201 - Disclosure - Summary of Significant Accounting Policies - Estimated useful life of property and equipment (Details)", "menuCat": "Details", "order": "95", "role": "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails", "shortName": "Summary of Significant Accounting Policies - Estimated useful life of property and equipment (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R96": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_9_30_2022_p44Q5s_h502JVvigcbN3Lw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredCosts", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240202 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "menuCat": "Details", "order": "96", "role": "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetailss", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R97": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "rnaz:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_9_30_2022_p44Q5s_h502JVvigcbN3Lw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240401 - Disclosure - Prepaid Expenses and Other Current Assets (Details)", "menuCat": "Details", "order": "97", "role": "http://www.transcodetherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetailss", "shortName": "Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R98": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_9_30_2022_p44Q5s_h502JVvigcbN3Lw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240501 - Disclosure - Property and Equipment (Details)", "menuCat": "Details", "order": "98", "role": "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipmentDetailss", "shortName": "Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R99": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_9_30_2022_p44Q5s_h502JVvigcbN3Lw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240601 - Disclosure - Accounts Payable and Accrued Expenses (Details)", "menuCat": "Details", "order": "99", "role": "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetailss", "shortName": "Accounts Payable and Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rnaz-20220930xs1.htm", "contextRef": "As_Of_9_30_2022_p44Q5s_h502JVvigcbN3Lw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_4Q107CC6Jku-mfKdfIbTTQ", "xsiNil": "false" } } }, "segmentCount": 52, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transcodetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transcodetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transcodetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transcodetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transcodetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transcodetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transcodetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transcodetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "rnaz_AccountsPayableAndAccruedExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount represents the value of accounts payable and accrued expense", "label": "Accounts Payable And Accrued Expense" } } }, "localname": "AccountsPayableAndAccruedExpense", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "rnaz_AccruedConsultingFeesCurrent": { "auth_ref": [], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetailss": { "order": 5.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Consulting Fees Current", "terseLabel": "General consulting fees", "verboseLabel": "Consulting fees" } } }, "localname": "AccruedConsultingFeesCurrent", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails", "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_AccruedGeneralExpenses": { "auth_ref": [], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetailss": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for general expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued General Expenses", "terseLabel": "General expenses" } } }, "localname": "AccruedGeneralExpenses", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_AccruedInsurancePremiums": { "auth_ref": [], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetailss": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for insurance premium. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Insurance Premiums", "terseLabel": "Insurance premiums" } } }, "localname": "AccruedInsurancePremiums", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails", "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_AccruedLicenseObligations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of accrued license obligations.", "label": "Accrued License Obligations", "terseLabel": "Accrued license obligations" } } }, "localname": "AccruedLicenseObligations", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_AccruedLicensePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for license payments.", "label": "Accrued License Payments", "terseLabel": "Accrued license payments" } } }, "localname": "AccruedLicensePayments", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_AccruedLicensePaymentsCurrent": { "auth_ref": [], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": { "order": 7.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetailss": { "order": 7.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for license payments. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued license payments current", "terseLabel": "Accrued license payments" } } }, "localname": "AccruedLicensePaymentsCurrent", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails", "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_AccruedProfessionalFeesPayable": { "auth_ref": [], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees Payable", "terseLabel": "Professional fees" } } }, "localname": "AccruedProfessionalFeesPayable", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "rnaz_AccruedResearchAndDevelopmentBillingsCurrent": { "auth_ref": [], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetailss": { "order": 6.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development billings. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued research and development billings current", "terseLabel": "Research and development billings", "verboseLabel": "R&D-related - CMOs, CROs, supplies, equipment and consulting" } } }, "localname": "AccruedResearchAndDevelopmentBillingsCurrent", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails", "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_AccumulatedRestrictedCommonStockIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accumulated restricted common stock issued.", "label": "Accumulated Restricted Common Stock Issued", "terseLabel": "Accumulated restricted common stock issued" } } }, "localname": "AccumulatedRestrictedCommonStockIssued", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss" ], "xbrltype": "sharesItemType" }, "rnaz_AccumulatedRestrictedCommonStockOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accumulated restricted common stock outstanding.", "label": "Accumulated Restricted Common Stock Outstanding", "verboseLabel": "Accumulated restricted common stock outstanding" } } }, "localname": "AccumulatedRestrictedCommonStockOutstanding", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss" ], "xbrltype": "sharesItemType" }, "rnaz_AccumulatedRestrictedCommonStockVested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accumulated restricted common stock vested.", "label": "Accumulated Restricted Common Stock Vested", "terseLabel": "Accumulated restricted common stock vested" } } }, "localname": "AccumulatedRestrictedCommonStockVested", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss" ], "xbrltype": "sharesItemType" }, "rnaz_AccumulatedUnrestrictedCommonStockIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of unrestricted common stock issued as of date.", "label": "Accumulated Unrestricted Common Stock Issued" } } }, "localname": "AccumulatedUnrestrictedCommonStockIssued", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "rnaz_AdditionalAmountForAllocatedShareOfOperatingExpensesPerSquareFoot": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additional amount for allocated share of operating expenses per square foot.", "label": "Additional Amount For Allocated Share Of Operating Expenses Per Square Foot", "terseLabel": "Additional amount for allocated share of operating expenses per square foot", "verboseLabel": "Allocated share of operating expenses" } } }, "localname": "AdditionalAmountForAllocatedShareOfOperatingExpensesPerSquareFoot", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.transcodetherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "rnaz_AdditionalSubleasePayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "It represents the amount of additional sublease payment.", "label": "Additional Sublease Payment", "terseLabel": "Additional sublease payment per month" } } }, "localname": "AdditionalSubleasePayment", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_AdjustmentForRoundingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pertains to adjustment for rounding.", "label": "Adjustment for rounding" } } }, "localname": "AdjustmentForRoundingMember", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails", "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetailss" ], "xbrltype": "domainItemType" }, "rnaz_AggregateGrantReceivableEstimatedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of aggregate estimated grant award receivable over a period of time.", "label": "Aggregate Grant Receivable, Estimated Amount", "terseLabel": "Expected award amount", "verboseLabel": "Expected Award amount" } } }, "localname": "AggregateGrantReceivableEstimatedAmount", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureDeferredGrantIncomeDetails", "http://www.transcodetherapeutics.com/role/DisclosureDeferredGrantIncomeDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_AmountPayableToContractResearchOrganizationsAndContractManufacturingOrganizations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount payable to Contract Research Organizations and Contract Manufacturing Organizations.", "label": "Amount Payable To Contract Research Organizations And Contract Manufacturing Organizations", "terseLabel": "Outstanding payables to CROs or CMOs" } } }, "localname": "AmountPayableToContractResearchOrganizationsAndContractManufacturingOrganizations", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_ChangesInFairValueOfDerivativeLiability": { "auth_ref": [], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of changes in the fair value of derivative liability.", "label": "Changes In The Fair Value Of Derivative Liability", "negatedLabel": "Change in fair value of derivative liabilities", "terseLabel": "Change in fair market value of derivative liabilities", "verboseLabel": "Change in fair value of derivative liabilities" } } }, "localname": "ChangesInFairValueOfDerivativeLiability", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3FinancialInstrumentsDetails", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss", "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations", "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperationss" ], "xbrltype": "monetaryItemType" }, "rnaz_CollaborativeArrangementExpensesIncurred": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total expenses incurred under the collaborative arrangement.", "label": "Collaborative Arrangement, Expenses Incurred", "terseLabel": "Total expenses incurred under the arrangement" } } }, "localname": "CollaborativeArrangementExpensesIncurred", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementAndLitigationDetails" ], "xbrltype": "monetaryItemType" }, "rnaz_CommonStockNumberOfVotesPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of votes that each common share is entitled.", "label": "Common Stock, Number Of Votes Per Share", "terseLabel": "Common stock voting rights per share" } } }, "localname": "CommonStockNumberOfVotesPerShare", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "integerItemType" }, "rnaz_CommonStockVotingRightsPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of votes per share for each share of common stock outstanding.", "label": "Common Stock Voting Rights Per Share", "terseLabel": "Common stock voting rights per share" } } }, "localname": "CommonStockVotingRightsPerShare", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss" ], "xbrltype": "perShareItemType" }, "rnaz_ComputerAndOfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member represents computer and office equipment.", "label": "Computer and office equipment" } } }, "localname": "ComputerAndOfficeEquipmentMember", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyPlantAndEquipmentTableDetails" ], "xbrltype": "domainItemType" }, "rnaz_ComputerBasedPhishingAttackHeldByReceivingBankPendingResolution": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of computer based phishing attack, held by receiving bank pending resolution.", "label": "Computer Based Phishing Attack Held By Receiving Bank Pending Resolution", "terseLabel": "Computer based phishing attack, held by receiving bank pending resolution." } } }, "localname": "ComputerBasedPhishingAttackHeldByReceivingBankPendingResolution", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_ComputerBasedPhishingAttackInvolving": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of computer based phishing attack involving.", "label": "Computer Based Phishing Attack Involving", "terseLabel": "Computer-based phishing attack involving, amount" } } }, "localname": "ComputerBasedPhishingAttackInvolving", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_ComputerBasedPhishingAttackInvolvingRecovery": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of computer based phishing attack involving recovery.", "label": "Computer Based Phishing Attack Involving Recovery", "terseLabel": "Computer-based phishing attack involving recovery, amount" } } }, "localname": "ComputerBasedPhishingAttackInvolvingRecovery", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_ComputerBasedPhishingAttackInvolvingRecoveryPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer based phishing attack involving recovery period.", "label": "Computer Based Phishing Attack Involving Recovery Period", "terseLabel": "Computer-based phishing attack involving recovery period" } } }, "localname": "ComputerBasedPhishingAttackInvolvingRecoveryPeriod", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "durationItemType" }, "rnaz_ConcentrationsOfCreditRiskAndOtherUncertaintiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for concentrations of credit risk and other uncertainties.", "label": "Concentrations Of Credit Risk And Other Uncertainties [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk" } } }, "localname": "ConcentrationsOfCreditRiskAndOtherUncertaintiesPolicyTextBlock", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "rnaz_ContractualObligationAmountCommittedToBePaidInYearOne": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation Committed to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation, Amount Committed To Be Paid in Year One", "terseLabel": "Amount the company has committed to pay in year one" } } }, "localname": "ContractualObligationAmountCommittedToBePaidInYearOne", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementAndLitigationDetails" ], "xbrltype": "monetaryItemType" }, "rnaz_ConversionDiscountPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion discount percentage.", "label": "Conversion Discount Percentage", "terseLabel": "Conversion discount percentage" } } }, "localname": "ConversionDiscountPercentage", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetails" ], "xbrltype": "percentItemType" }, "rnaz_ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of conversion of convertible promissory notes including embedded derivatives to common stock.", "label": "Conversion of Convertible Promissory Notes Including Embedded Derivative To Common Stock", "terseLabel": "Conversion of convertible promissory notes, including embedded derivative, to common stock" } } }, "localname": "ConversionOfConvertiblePromissoryNotesIncludingEmbeddedDerivativeToCommonStock", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "rnaz_CostOfExtendedOptionAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of extended option agreement.", "label": "Cost Of Extended Option Agreement", "terseLabel": "Cost of extended option agreement" } } }, "localname": "CostOfExtendedOptionAgreement", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_CostOfOptionAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of option agreement.", "label": "Cost Of Option Agreement", "terseLabel": "Cost of option agreement" } } }, "localname": "CostOfOptionAgreement", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_DebtDiscountsAssociatedWithDerivativeLiabilitiesOfConvertiblePromissoryNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discounts associated with derivative liabilities of convertible promissory notes.", "label": "Debt Discounts Associated With Derivative Liabilities Of Convertible Promissory Notes", "terseLabel": "Debt discounts associated with derivative liabilities of convertible promissory notes" } } }, "localname": "DebtDiscountsAssociatedWithDerivativeLiabilitiesOfConvertiblePromissoryNotes", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "rnaz_DeferredGrantIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Grant Income" } } }, "localname": "DeferredGrantIncomeAbstract", "nsuri": "http://www.transcodetherapeutics.com/20220930", "xbrltype": "stringItemType" }, "rnaz_DeferredGrantIncomeDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of deferred grant income.", "label": "Deferred Grant Income Disclosure [Text Block]", "terseLabel": "Grant Income", "verboseLabel": "Deferred Grant Income" } } }, "localname": "DeferredGrantIncomeDisclosureTextBlock", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureDeferredGrantIncome", "http://www.transcodetherapeutics.com/role/DisclosureGrantIncome" ], "xbrltype": "textBlockItemType" }, "rnaz_DeferredOfferingCostsAdjustedIntoAdditionalPaidInCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred offering costs adjusted into additional paid-in capital in connection with IPO.", "label": "Deferred offering costs adjusted into additional paid-in capital", "verboseLabel": "Deferred offering costs adjusted into additional paid-in capital in connection with IPO" } } }, "localname": "DeferredOfferingCostsAdjustedIntoAdditionalPaidInCapital", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "rnaz_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred offering costs included in accounts payable and accrued expenses.", "label": "Deferred Offering Costs Included In Accounts Payable And Accrued Expenses", "terseLabel": "Deferred offering costs included in accounts payable and accrued expenses" } } }, "localname": "DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "rnaz_DeferredTaxAssetsCapitalizedPatentAndOtherAssets": { "auth_ref": [], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as Capitalized patent and other costs.", "label": "Deferred Tax Assets Capitalized Patent And Other Assets", "terseLabel": "Capitalized patent and other costs" } } }, "localname": "DeferredTaxAssetsCapitalizedPatentAndOtherAssets", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "rnaz_DeferredTaxAssetsCapitalizedResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development.", "label": "Deferred Tax Assets, Capitalized Research and Development", "terseLabel": "Capitalized research and development" } } }, "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "rnaz_DefinedEmployeeStockPurchasePlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Employee Stock Purchase Plan", "label": "Employee Stock Purchase Plan" } } }, "localname": "DefinedEmployeeStockPurchasePlan", "nsuri": "http://www.transcodetherapeutics.com/20220930", "xbrltype": "stringItemType" }, "rnaz_EmergingGrowthCompanyStatusPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for Emerging Growth Company Status.", "label": "Emerging Growth Company Status [Policy Text Block]", "terseLabel": "Emerging Growth Company Status" } } }, "localname": "EmergingGrowthCompanyStatusPolicyTextBlock", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "rnaz_EmployeeStockPurchasePlanTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Stock Purchase Plan [Text block]", "label": "Employee Stock Purchase Plan [Text block]", "terseLabel": "Employee Stock Purchase Plan" } } }, "localname": "EmployeeStockPurchasePlanTextBlock", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureEmployeeStockPurchasePlan" ], "xbrltype": "textBlockItemType" }, "rnaz_ExtinguishmentOfLiabilityOnConversionOfNotes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the extinguishment of liability on conversion of Notes.", "label": "Extinguishment Of Liability On Conversion Of Notes", "terseLabel": "Extinguishment of liability on conversion of Notes" } } }, "localname": "ExtinguishmentOfLiabilityOnConversionOfNotes", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "rnaz_ExtinguishmentOfLiabilityOnExerciseOfWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the extinguishment of liability on exercise of warrants.", "label": "Extinguishment Of Liability On Exercise Of Warrants", "terseLabel": "Extinguishment of liability on exercise of warrants" } } }, "localname": "ExtinguishmentOfLiabilityOnExerciseOfWarrants", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "rnaz_ExtinguishmentOfWarrantLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of extinguishment of warrant liability.", "label": "Extinguishment Of Warrant Liability", "terseLabel": "Extinguishment of warrant liability on warrant exercise" } } }, "localname": "ExtinguishmentOfWarrantLiability", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "rnaz_FairValueOfWarrantLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of warrant liability associated with warrant exercise.", "label": "Fair value of warrant liability", "verboseLabel": "Fair value of warrant liability associated with warrant exercise" } } }, "localname": "FairValueOfWarrantLiability", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "rnaz_FirstTwelveMonthsOfLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the first 12 months of lease.", "label": "First 12 Months of Lease" } } }, "localname": "FirstTwelveMonthsOfLeaseMember", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "rnaz_GeneralExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": { "order": 6.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of general expenses.", "label": "General Expenses, Current", "terseLabel": "General expenses" } } }, "localname": "GeneralExpensesCurrent", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "rnaz_GrantIncomeOther": { "auth_ref": [], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of grant income recognized during the period classified as other.", "label": "Grant Income, Other", "terseLabel": "Grant income", "verboseLabel": "Grant income recognized" } } }, "localname": "GrantIncomeOther", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureDeferredGrantIncomeDetails", "http://www.transcodetherapeutics.com/role/DisclosureDeferredGrantIncomeDetailss", "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations", "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperationss" ], "xbrltype": "monetaryItemType" }, "rnaz_GrantIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for grant income.", "label": "Grant Income Policy [Policy Text Block]", "terseLabel": "Grant Income" } } }, "localname": "GrantIncomePolicyPolicyTextBlock", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "rnaz_GrantIncomeReceivable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of grant income receivable.", "label": "Grant Income Receivable", "terseLabel": "Grant income receivable" } } }, "localname": "GrantIncomeReceivable", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureDeferredGrantIncomeDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_GrantReceivableEstimatedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated grant award receivable under year two.", "label": "Grant Receivable, Estimated Amount", "terseLabel": "Amount expects to receive under year two" } } }, "localname": "GrantReceivableEstimatedAmount", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rnaz_GrossProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The gross cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Gross Proceeds from Issuance Initial Public Offering", "terseLabel": "Gross proceeds" } } }, "localname": "GrossProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityIpoDetails" ], "xbrltype": "monetaryItemType" }, "rnaz_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingIncreaseDecreaseInInterestPayableNet": { "auth_ref": [], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid, excluding the increase (decrease) during the reporting period in interest payable.", "label": "Increase Decrease In Accounts Payable And Accrued Liabilities Excluding Increase Decrease In Interest Payable Net", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingIncreaseDecreaseInInterestPayableNet", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "rnaz_IncreaseDecreaseInGrantReceivable": { "auth_ref": [], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "It represents the amount of increase (decrease) in grant receivable.", "label": "Increase Decrease In Grant Receivable", "negatedLabel": "Grants receivable" } } }, "localname": "IncreaseDecreaseInGrantReceivable", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "rnaz_InterestOnSubscriptionReceivable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest on subscription receivable.", "label": "Interest On Subscription Receivable", "terseLabel": "Interest on subscription receivable", "verboseLabel": "Accrued interest on subscriptions receivable" } } }, "localname": "InterestOnSubscriptionReceivable", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficit", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "monetaryItemType" }, "rnaz_InterestPayableNoncurrent": { "auth_ref": [], "calculation": { "http://www.transcodetherapeutics.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of noncurrent accrued interest payable on debt.", "label": "Interest Payable, Noncurrent", "terseLabel": "Accrued interest - convertible promissory notes", "verboseLabel": "Accrued interest" } } }, "localname": "InterestPayableNoncurrent", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "monetaryItemType" }, "rnaz_InterestRateForSubscriptionsReceivable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate for subscriptions receivable.", "label": "Interest Rate For Subscriptions Receivable", "terseLabel": "Interest rate for subscriptions receivable" } } }, "localname": "InterestRateForSubscriptionsReceivable", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss" ], "xbrltype": "percentItemType" }, "rnaz_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member represents laboratory equipment.", "label": "Laboratory equipment", "terseLabel": "Laboratory equipment" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyPlantAndEquipmentTableDetails" ], "xbrltype": "domainItemType" }, "rnaz_MassachusettsBiomedicalInitiativesInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Massachusetts Biomedical Initiatives, Inc. (\"MBI\").", "label": "Massachusetts Biomedical Initiatives, Inc. (\"MBI\")" } } }, "localname": "MassachusettsBiomedicalInitiativesInc.Member", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.transcodetherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "rnaz_MaximumNumberOfSharesWhichCompanyIsAuthorizedToIssue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of shares which the Company is authorized to issue.", "label": "Maximum Number Of Shares Which The Company Is Authorized To Issue", "terseLabel": "Maximum number of shares which the Company is authorized to issue" } } }, "localname": "MaximumNumberOfSharesWhichCompanyIsAuthorizedToIssue", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss" ], "xbrltype": "sharesItemType" }, "rnaz_MaximumTotalMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum total milestone payments.", "label": "Maximum Total Milestone Payments", "terseLabel": "Maximum total milestone payments" } } }, "localname": "MaximumTotalMilestonePayments", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_MilestonePaymentDueWhenEnrollmentOfFirstPatientInPhaseIiClinicalTrialOfTherapeuticProductOrProcess": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone payment due when enrollment of first patient in a phase II clinical trial of a therapeutic product or process.", "label": "Milestone Payment Due When Enrollment Of First Patient In a Phase II Clinical Trial Of a Therapeutic Product Or Process", "terseLabel": "Enrollment of first patient in a phase II clinical trial of a therapeutic product or process", "verboseLabel": "Milestone payment due when enrollment of first patient in a phase II clinical trial of a therapeutic product or process" } } }, "localname": "MilestonePaymentDueWhenEnrollmentOfFirstPatientInPhaseIiClinicalTrialOfTherapeuticProductOrProcess", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_MilestonePaymentDueWhenEnrollmentOfFirstPatientInPhaseIiiClinicalTrialOfTherapeuticProductOrProcess": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone payment due when enrollment of first patient in a phase III clinical trial of a therapeutic product or process.", "label": "Milestone Payment Due When Enrollment Of First Patient In a Phase III Clinical Trial Of a Therapeutic Product Or Process", "terseLabel": "Enrollment of first patient in a phase III clinical trial of a therapeutic product or process", "verboseLabel": "Milestone payment due when enrollment of first patient in a phase III clinical trial of a therapeutic product or process" } } }, "localname": "MilestonePaymentDueWhenEnrollmentOfFirstPatientInPhaseIiiClinicalTrialOfTherapeuticProductOrProcess", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_MilestonePaymentDueWhenFilingOfApplicationForRegulatoryApprovalOfClinicalDiagnosticProductOrProcess": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone payment due when filing of an application for regulatory approval of a clinical diagnostic product or process.", "label": "Milestone Payment Due When Filing Of an Application For Regulatory Approval Of a Clinical Diagnostic Product Or Process", "terseLabel": "Filing of an application for regulatory approval of a clinical diagnostic product or process", "verboseLabel": "Milestone payment due when filing of an application for regulatory approval of a clinical diagnostic product or process" } } }, "localname": "MilestonePaymentDueWhenFilingOfApplicationForRegulatoryApprovalOfClinicalDiagnosticProductOrProcess", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_MilestonePaymentDueWhenFirstCommercialSaleOfTherapeuticProductOrProcess": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone payment due when first commercial sale of a therapeutic product or process.", "label": "Milestone Payment Due When First Commercial Sale Of a Therapeutic Product Or Process", "terseLabel": "First commercial sale of a therapeutic product or process", "verboseLabel": "Milestone payment due when first commercial sale of a therapeutic product or process" } } }, "localname": "MilestonePaymentDueWhenFirstCommercialSaleOfTherapeuticProductOrProcess", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_MilestonePaymentDueWhenFirstRegulatoryApprovalOfClinicalDiagnosticProductOrProcess": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone payment due when first regulatory approval of a clinical diagnostic product or process.", "label": "Milestone Payment Due When First Regulatory Approval Of a Clinical Diagnostic Product Or Process", "terseLabel": "First regulatory approval of a clinical diagnostic product or process", "verboseLabel": "Milestone payment due when first regulatory approval of a clinical diagnostic product or process" } } }, "localname": "MilestonePaymentDueWhenFirstRegulatoryApprovalOfClinicalDiagnosticProductOrProcess", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_MinimumAnnualLicenseFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Minimum annual license fee.", "label": "Minimum Annual License Fee", "terseLabel": "Minimum annual license fee" } } }, "localname": "MinimumAnnualLicenseFee", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_MinimumAnnualLicenseFeeForPatentFamily1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Minimum annual license fee for Patent Family 1.", "label": "Minimum Annual License Fee For Patent Family 1", "terseLabel": "Minimum annual license fee for Patent Family 1" } } }, "localname": "MinimumAnnualLicenseFeeForPatentFamily1", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_MinimumAnnualLicenseFeeRelatedToPatentFamily2": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Minimum annual license fee related to Patent Family 2.", "label": "Minimum Annual License Fee Related To Patent Family 2", "terseLabel": "Minimum annual license fee related to Patent Family 2" } } }, "localname": "MinimumAnnualLicenseFeeRelatedToPatentFamily2", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_NetLossPerShareAntiDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all anti-dilutive potential common shares or units outstanding during the reporting period.", "label": "Net Loss per share, anti-diluted", "terseLabel": "Net Loss per share, anti-diluted" } } }, "localname": "NetLossPerShareAntiDiluted", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetEarningsLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "rnaz_NoteEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Eight.", "label": "Note Eight" } } }, "localname": "NoteEightMember", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "domainItemType" }, "rnaz_NoteElevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Eleven.", "label": "Note Eleven" } } }, "localname": "NoteElevenMember", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "domainItemType" }, "rnaz_NoteFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Five.", "label": "Note Five" } } }, "localname": "NoteFiveMember", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "domainItemType" }, "rnaz_NoteFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Four.", "label": "Note Four" } } }, "localname": "NoteFourMember", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "domainItemType" }, "rnaz_NoteFourteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Fourteen.", "label": "Note Fourteen" } } }, "localname": "NoteFourteenMember", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "domainItemType" }, "rnaz_NoteNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Nine.", "label": "Note Nine" } } }, "localname": "NoteNineMember", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "domainItemType" }, "rnaz_NoteOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note One.", "label": "Note One" } } }, "localname": "NoteOneMember", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetails" ], "xbrltype": "domainItemType" }, "rnaz_NoteOneWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note One Warrants", "label": "Note One Warrants" } } }, "localname": "NoteOneWarrantsMember", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetails" ], "xbrltype": "domainItemType" }, "rnaz_NoteSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Seven.", "label": "Note Seven" } } }, "localname": "NoteSevenMember", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "domainItemType" }, "rnaz_NoteSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Six.", "label": "Note Six" } } }, "localname": "NoteSixMember", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "domainItemType" }, "rnaz_NoteTenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Ten.", "label": "Note Ten" } } }, "localname": "NoteTenMember", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "domainItemType" }, "rnaz_NoteThirteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Thirteen.", "label": "Note Thirteen" } } }, "localname": "NoteThirteenMember", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "domainItemType" }, "rnaz_NoteThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Three.", "label": "Note Three" } } }, "localname": "NoteThreeMember", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "domainItemType" }, "rnaz_NoteTwelveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Twelve.", "label": "Note Twelve" } } }, "localname": "NoteTwelveMember", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "domainItemType" }, "rnaz_NoteTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Two.", "label": "Note Two" } } }, "localname": "NoteTwoMember", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "domainItemType" }, "rnaz_NoticePeriodForCancelationOfLease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notice period for cancelation of lease.", "label": "Notice Period For Cancelation Of Lease", "terseLabel": "Notice period for cancelation of lease" } } }, "localname": "NoticePeriodForCancelationOfLease", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "xbrltype": "durationItemType" }, "rnaz_NoticePeriodForTerminatingLicense": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notice period for terminating License.", "label": "Notice Period For Terminating License", "terseLabel": "Notice period for terminating License" } } }, "localname": "NoticePeriodForTerminatingLicense", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "durationItemType" }, "rnaz_NumberOfConvertiblePromissoryNotes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of convertible promissory notes issued during period.", "label": "Number Of Convertible Promissory Notes", "terseLabel": "Number of convertible promissory notes" } } }, "localname": "NumberOfConvertiblePromissoryNotes", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "integerItemType" }, "rnaz_NumberOfLaboratoryBenchRented": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of laboratory bench rented.", "label": "Number Of Laboratory Bench Rented", "terseLabel": "Number of laboratory bench rented" } } }, "localname": "NumberOfLaboratoryBenchRented", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "xbrltype": "integerItemType" }, "rnaz_NumberOfPurchasersForRestrictedSharesInExchangeForSubscriptionsReceivable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of purchasers for restricted shares in exchange for subscriptions receivable", "label": "Number Of Purchasers For Restricted Shares In Exchange For Subscriptions Receivable", "terseLabel": "Number of purchasers for restricted shares in exchange for subscriptions receivable" } } }, "localname": "NumberOfPurchasersForRestrictedSharesInExchangeForSubscriptionsReceivable", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss" ], "xbrltype": "integerItemType" }, "rnaz_NumberOfSharesOfCommonStockSubjectToWarrantsAsPercentToNumberOfSharesOfCommonStockIntoWhichNoteOneConverts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares of common stock subject to the warrants as a percent to the number of shares of Common Stock into which Note One converts.", "label": "The number of shares of common stock subject to the warrants as a percent to the number of shares of Common Stock into which Note One converts", "terseLabel": "The number of shares of common stock subject to the warrants as a percent to the number of shares of Common Stock into which Note One converts" } } }, "localname": "NumberOfSharesOfCommonStockSubjectToWarrantsAsPercentToNumberOfSharesOfCommonStockIntoWhichNoteOneConverts", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetails" ], "xbrltype": "pureItemType" }, "rnaz_OfferingCostsIncurredButNotYetPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for offering costs that have occurred.", "label": "Offering Costs Incurred But Not Yet Paid", "verboseLabel": "Deferred offering costs included in accounts payable and accrued expenses" } } }, "localname": "OfferingCostsIncurredButNotYetPaid", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rnaz_OneTimeNonRefundableFeeOfLicenseAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "One-time non-refundable fee for license of license agreement.", "label": "One-time Non-refundable Fee Of License Agreement", "terseLabel": "One-time non-refundable fee of license agreement" } } }, "localname": "OneTimeNonRefundableFeeOfLicenseAgreement", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_OperatingExpensesIncreasedByFivePercentageMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the operating expenses increased by 5% scenario.", "label": "5% Increase in Operating Expenses" } } }, "localname": "OperatingExpensesIncreasedByFivePercentageMember", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "rnaz_OperatingLeaseBaseRentPerMonth": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of monthly base rent in operating lease.", "label": "Operating Lease, Base Rent Per Month", "terseLabel": "Base rent per month" } } }, "localname": "OperatingLeaseBaseRentPerMonth", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "rnaz_OtherOfferingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of other offering costs.", "label": "Other Offering Costs", "terseLabel": "Other offering expenses" } } }, "localname": "OtherOfferingCosts", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_PagliucaHarvardLifeLabMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pagliuca Harvard Life Lab.", "label": "Pagliuca Harvard Life Lab" } } }, "localname": "PagliucaHarvardLifeLabMember", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "xbrltype": "domainItemType" }, "rnaz_PaymentOfDeferredOfferingCosts": { "auth_ref": [], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for payments of deferred offering costs.", "label": "Payment of Deferred Offering Costs", "negatedLabel": "Payments of deferred offering costs" } } }, "localname": "PaymentOfDeferredOfferingCosts", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "rnaz_PaymentsOfDeferredOfferingCost": { "auth_ref": [], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for payments of deferred offering costs additional.", "label": "Payments Of Deferred Offering Cost", "terseLabel": "Payments of deferred offering costs - additions" } } }, "localname": "PaymentsOfDeferredOfferingCost", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rnaz_PaymentsToRelatedPartyInOperatingActivities": { "auth_ref": [], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payments to related party in operating activities.", "label": "Payments To Related Party In Operating Activities", "negatedLabel": "Due to related parties" } } }, "localname": "PaymentsToRelatedPartyInOperatingActivities", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rnaz_PercentageOfIncreaseInBaseRent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of Increase in Base Rent", "label": "Percentage of Increase in Base Rent", "verboseLabel": "Percentage of increase in base rent" } } }, "localname": "PercentageOfIncreaseInBaseRent", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "rnaz_PercentageOfLimitationOfUsageOfOperatingLosses": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of limitation of usage of operating losses .", "label": "Percentage Of Limitation Of Usage Of Operating Losses", "terseLabel": "Percentage of limitation of usage of operating losses" } } }, "localname": "PercentageOfLimitationOfUsageOfOperatingLosses", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "rnaz_PeriodAfterFirstCommercialSaleThatLicenseShallContinueIfNotTerminatedByCompany": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period after the first commercial sale that the License shall continue if not terminated by the company.", "label": "Period After The First Commercial Sale That The License Shall Continue If Not Terminated By The Company", "terseLabel": "Period after the first commercial sale that the License shall continue if not terminated by the company" } } }, "localname": "PeriodAfterFirstCommercialSaleThatLicenseShallContinueIfNotTerminatedByCompany", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "durationItemType" }, "rnaz_PeriodWithinEachAnniversaryOfEffectiveDateOfLicenseThatMinimumAnnualLicenseFeeMustBePaid": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period within each anniversary of the effective date of the License that minimum annual license fee must be paid.", "label": "Period Within Each Anniversary Of The Effective Date Of The License That Minimum Annual License Fee Must Be Paid", "terseLabel": "Period within each anniversary of the effective date of the License that minimum annual license fee must be paid" } } }, "localname": "PeriodWithinEachAnniversaryOfEffectiveDateOfLicenseThatMinimumAnnualLicenseFeeMustBePaid", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "durationItemType" }, "rnaz_PeriodWithinWhichMilestonePaymentsShouldBePaidUponAchievementOfMilestone": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period within which the milestone payments should be paid upon achievement of the milestone.", "label": "Period Within Which The Milestone Payments Should Be Paid Upon Achievement Of The Milestone", "terseLabel": "Period within which the milestone payments should be paid upon achievement of the milestone" } } }, "localname": "PeriodWithinWhichMilestonePaymentsShouldBePaidUponAchievementOfMilestone", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "durationItemType" }, "rnaz_PossiblePercentageOfIncreaseInOperatingExpenses": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Possible Percentage Of Increase In Operating Expenses", "label": "Possible Percentage Of Increase In Operating Expenses", "terseLabel": "Possible percentage of increase in operating expenses" } } }, "localname": "PossiblePercentageOfIncreaseInOperatingExpenses", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "rnaz_PreMoneyValuationLimitForNoteConversion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Pre-money valuation limit for note conversion.", "label": "Pre-money Valuation Limit For Note Conversion", "terseLabel": "Pre-money valuation limit for note conversion" } } }, "localname": "PreMoneyValuationLimitForNoteConversion", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "rnaz_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of prepaid expenses and other current assets.", "label": "Prepaid Expenses And Other Current Assets [Table Text Block]", "terseLabel": "Schedule of prepaid expenses and other current assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables", "http://www.transcodetherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTabless" ], "xbrltype": "textBlockItemType" }, "rnaz_ProceedsFromEscrowDepositsAppliedToExerciseOfWarrants": { "auth_ref": [], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash inflow received during the period as an Escrow deposit on account for application (deposits to retire or pay down) against an amount of Exercise of warrants.", "label": "Proceeds from Escrow Deposits Applied to Exercise Of Warrants", "terseLabel": "Proceeds from escrow payment for warrant exercise", "verboseLabel": "Proceeds from escrow for warrant exercise advances" } } }, "localname": "ProceedsFromEscrowDepositsAppliedToExerciseOfWarrants", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "rnaz_ProceedsFromSubscriptionReceivable": { "auth_ref": [], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to proceeds from subscription receivable.", "label": "Proceeds From Subscription Receivable", "terseLabel": "Proceeds from subscription receivable" } } }, "localname": "ProceedsFromSubscriptionReceivable", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "rnaz_ProceedsFromSubscriptionReceivableSource2": { "auth_ref": [], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to proceeds from subscription receivable.", "label": "Proceeds From Subscription Receivable Source2", "negatedLabel": "Proceeds from subscription receivable", "terseLabel": "Proceeds from subscription receivable" } } }, "localname": "ProceedsFromSubscriptionReceivableSource2", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "monetaryItemType" }, "rnaz_PropertyPlantAndEquipmentSEstimatedUsefulLifePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property and Plant Equipment.", "label": "Property Plant And Equipment's Estimated Useful Life [Policy Text Block]", "terseLabel": "Summary of estimated useful life of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentSEstimatedUsefulLifePolicyTextBlock", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTabless" ], "xbrltype": "textBlockItemType" }, "rnaz_RedemptionPremiumAsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The excess of the fair value of consideration transferred as a percent.", "label": "Redemption Premium (As A Percent)", "terseLabel": "Redemption premium (as a percent)" } } }, "localname": "RedemptionPremiumAsPercent", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityIpoDetails" ], "xbrltype": "percentItemType" }, "rnaz_ReimbursementOfLicensorsPatentCostsAtExecutionOfLicense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reimbursement of Licensor's patent costs at execution of the License.", "label": "Reimbursement Of Licensor's Patent Costs At Execution Of The License", "terseLabel": "Reimbursement of Licensor's patent costs at execution of the License" } } }, "localname": "ReimbursementOfLicensorsPatentCostsAtExecutionOfLicense", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_RepaymentOfSubscriptionReceivable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of repayment towards subscription receivable.", "label": "Repayment of Subscription Receivable", "verboseLabel": "Repayment of subscription receivable" } } }, "localname": "RepaymentOfSubscriptionReceivable", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_RestrictedSharesIssuedInExchangeForSubscriptionsReceivable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted shares issued in exchange for subscriptions receivable.", "label": "Restricted Shares Issued In Exchange For Subscriptions Receivable", "terseLabel": "Restricted shares issued in exchange for subscriptions receivable" } } }, "localname": "RestrictedSharesIssuedInExchangeForSubscriptionsReceivable", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss" ], "xbrltype": "sharesItemType" }, "rnaz_ReverseStockSplitPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for Reverse Stock Split.", "label": "Reverse Stock Split [Policy Text Block]", "terseLabel": "Reverse Stock Split" } } }, "localname": "ReverseStockSplitPolicyTextBlock", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "rnaz_RoyaltiesCalculatedAsPercentageOfAnyAndAllSublicenseIncome": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalties calculated as a percentage of any and all sublicense income.", "label": "Royalties Calculated As a Percentage Of Any And All Sublicense Income", "terseLabel": "Royalties calculated as a percentage of any and all sublicense income" } } }, "localname": "RoyaltiesCalculatedAsPercentageOfAnyAndAllSublicenseIncome", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "percentItemType" }, "rnaz_RoyaltiesCalculatedAsPercentageToOnNetSalesOfLicensedProductsForClinicalDiagnosticProductsAndProcesses": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalties calculated as a percentage to on net sales of licensed products for clinical diagnostic products and processes.", "label": "Royalties Calculated As a Percentage To On Net Sales Of Licensed Products For Clinical Diagnostic Products And Processes", "terseLabel": "Royalties calculated as a percentage to on net sales of licensed products for clinical diagnostic products and processes" } } }, "localname": "RoyaltiesCalculatedAsPercentageToOnNetSalesOfLicensedProductsForClinicalDiagnosticProductsAndProcesses", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "percentItemType" }, "rnaz_RoyaltiesCalculatedAsPercentageToOnNetSalesOfLicensedProductsForTherapeuticProductsOrProcesses": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalties calculated as a percentage to on net sales of licensed products for therapeutic products or processes.", "label": "Royalties Calculated As a Percentage To On Net Sales Of Licensed Products For Therapeutic Products Or Processes", "terseLabel": "Royalties calculated as a percentage to on net sales of licensed products for therapeutic products or processes" } } }, "localname": "RoyaltiesCalculatedAsPercentageToOnNetSalesOfLicensedProductsForTherapeuticProductsOrProcesses", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "percentItemType" }, "rnaz_RoyaltyPercentageBeyondTermOfLicense": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty percentage beyond the term of the License.", "label": "Royalty Percentage Beyond The Term Of The License", "terseLabel": "Royalty percentage beyond the term of the License" } } }, "localname": "RoyaltyPercentageBeyondTermOfLicense", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "percentItemType" }, "rnaz_ScheduleOfMilestonePaymentsCompanyShallPayToLicensorTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of milestone payments the Company shall pay to Licensor.", "label": "Schedule Of Milestone Payments Company Shall Pay To Licensor [Table Text Block]", "terseLabel": "Schedule of milestone payments the Company shall pay to Licensor" } } }, "localname": "ScheduleOfMilestonePaymentsCompanyShallPayToLicensorTableTextBlock", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesTables", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesTabless" ], "xbrltype": "textBlockItemType" }, "rnaz_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards granted during period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share based Compensation Arrangement By Share based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term 2", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetailss" ], "xbrltype": "durationItemType" }, "rnaz_ShareBasedCompensationArrangementPurchasePriceForSignificantShareholders": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The exercise price for a share based compensation award as a percent of fair value to be used as a minimum for shareholders owning a specified amount of shares outstanding.", "label": "Share based Compensation Arrangement Purchase Price For Significant Shareholders", "verboseLabel": "Exercise price as a percentage of fair value for shareholders owning specified minimum amount" } } }, "localname": "ShareBasedCompensationArrangementPurchasePriceForSignificantShareholders", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss" ], "xbrltype": "percentItemType" }, "rnaz_ShareBasedCompensationArrangementPurchasePriceForSignificantShareholders.": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The option terms for a share based compensation award as a percent of fair value to be used as a minimum for shareholders owning a specified amount of shares outstanding.", "label": "Share based Compensation Arrangement Purchase Price For Significant Shareholders.", "verboseLabel": "Option terms for shareholders owning specified minimum amount" } } }, "localname": "ShareBasedCompensationArrangementPurchasePriceForSignificantShareholders.", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss" ], "xbrltype": "durationItemType" }, "rnaz_SignificantShareholderThresholdPercentageOwnership": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The ownership threshold used to determine if a recipient of a share based compensation award uses a different percentage of fair value for exercise price of awards.", "label": "Significant Shareholder Threshold Percentage Ownership", "verboseLabel": "Significant shareholder threshold used for determining exercise price" } } }, "localname": "SignificantShareholderThresholdPercentageOwnership", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss" ], "xbrltype": "percentItemType" }, "rnaz_StockIssuedDuringPeriodSharesWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares of stock issued as a result of the exercise of warrants.", "label": "Stock Issued During Period, Shares, Warrants Exercised", "terseLabel": "Exercise of warrants (in shares)", "verboseLabel": "Number of shares upon warrant exercise (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetails", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "sharesItemType" }, "rnaz_StockIssuedDuringPeriodValueWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of warrants.", "label": "Stock Issued During Period, Value, Warrants Exercised", "terseLabel": "Exercise of warrants" } } }, "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "monetaryItemType" }, "rnaz_StockOptionAndIncentivePlan2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Option and Incentive Plan 2020", "label": "Stock Option and Incentive Plan 2020" } } }, "localname": "StockOptionAndIncentivePlan2020Member", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationDetailss" ], "xbrltype": "domainItemType" }, "rnaz_StockOptionAndIncentivePlan2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to stock option incentive plan 2021.", "label": "Stock Option and Incentive Plan 2021" } } }, "localname": "StockOptionAndIncentivePlan2021Member", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss" ], "xbrltype": "domainItemType" }, "rnaz_StrategicCollaborationAgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of strategic collaboration agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Strategic Collaboration Agreement, Term", "terseLabel": "Collaboration agreement term" } } }, "localname": "StrategicCollaborationAgreementTerm", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementAndLitigationDetails" ], "xbrltype": "durationItemType" }, "rnaz_TaxYear2017AndPriorYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the tax year 2017 and prior years.", "label": "Tax Year 2017 And Prior Years [Member]", "terseLabel": "2017 and Prior Years" } } }, "localname": "TaxYear2017AndPriorYearsMember", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rnaz_TermOfGrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between award and receivable of grant income, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Term of Grant", "terseLabel": "Grant term (in years)" } } }, "localname": "TermOfGrant", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureDeferredGrantIncomeDetails", "http://www.transcodetherapeutics.com/role/DisclosureDeferredGrantIncomeDetailss" ], "xbrltype": "durationItemType" }, "rnaz_TermsOfExtendedOptionAgreementWithLicensor": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Terms of extended option agreement with Licensor.", "label": "Terms Of Extended Option Agreement With Licensor", "terseLabel": "Terms of extended option agreement with Licensor" } } }, "localname": "TermsOfExtendedOptionAgreementWithLicensor", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "durationItemType" }, "rnaz_TotalAdditionalSubleasePayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "It represents the amount of total additional sublease payment.", "label": "Total Additional Sublease Payment", "terseLabel": "Total additional sublease payment per month" } } }, "localname": "TotalAdditionalSubleasePayment", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "xbrltype": "monetaryItemType" }, "rnaz_UnderwriterWarrantsPercentageOfInitialPublicOfferingPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of initial public offering price underwriter warrants issued.", "label": "Underwriter Warrants Percentage Of Initial Public Offering Price", "terseLabel": "Underwriter Initial public offering price (in percentage)" } } }, "localname": "UnderwriterWarrantsPercentageOfInitialPublicOfferingPrice", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetailss", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsScheduleOfAssumptionsOfFairValueOfWarrantLiabilityDetails" ], "xbrltype": "percentItemType" }, "rnaz_UnderwritingDiscountsAndCommissionsPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of underwriting discounts and commissions paid from gross proceeds of IPO.", "label": "Underwriting discounts and commissions paid", "verboseLabel": "Underwriting discounts and commissions paid from gross proceeds of IPO" } } }, "localname": "UnderwritingDiscountsAndCommissionsPaid", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "rnaz_UniversityOfTexasM.D.AndersonCancerCenterMdAndersonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to The University of Texas M. D. Anderson Cancer Center (\"MD Anderson\").", "label": "The University of Texas M. D. Anderson Cancer Center (\"MD Anderson\")", "terseLabel": "The University of Texas M. D. Anderson Cancer Center (\"MD Anderson\")" } } }, "localname": "UniversityOfTexasM.D.AndersonCancerCenterMdAndersonMember", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementAndLitigationDetails" ], "xbrltype": "domainItemType" }, "rnaz_WarrantDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of warrants.", "label": "Warrant Disclosure [Text Block]", "terseLabel": "Warrants" } } }, "localname": "WarrantDisclosureTextBlock", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrants", "http://www.transcodetherapeutics.com/role/DisclosureWarrantss" ], "xbrltype": "textBlockItemType" }, "rnaz_WarrantsIssuedDuringPeriodForUnderwriters": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants issued during period for underwriters.", "label": "Warrants Issued During Period For Underwriters", "terseLabel": "Shares issuable on exercise of underwriter warrants" } } }, "localname": "WarrantsIssuedDuringPeriodForUnderwriters", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShareComputationOfDilutedEarningsLossPerWeightedAverageShareOutstandingDetails" ], "xbrltype": "sharesItemType" }, "rnaz_WeightedAverageCommonSharesOutstandingAntiDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating anti-diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted-average common shares outstanding, anti-diluted", "terseLabel": "Weighted-average common shares outstanding, anti-diluted" } } }, "localname": "WeightedAverageCommonSharesOutstandingAntiDiluted", "nsuri": "http://www.transcodetherapeutics.com/20220930", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetEarningsLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r222", "r223", "r306", "r333", "r492", "r494" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementAndLitigationDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.transcodetherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r359", "r460", "r479", "r489", "r490", "r506", "r510", "r514", "r543", "r560", "r561", "r562", "r563", "r564", "r565" ], "lang": { "en-us": { "role": { "label": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetailss", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r359", "r460", "r479", "r489", "r490", "r506", "r510", "r514", "r543", "r560", "r561", "r562", "r563", "r564", "r565" ], "lang": { "en-us": { "role": { "label": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetailss", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r351", "r359", "r436", "r460", "r479", "r489", "r490", "r506", "r510", "r514", "r543", "r561", "r562", "r563", "r564", "r565" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetailss", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r351", "r359", "r436", "r460", "r479", "r489", "r490", "r506", "r510", "r514", "r543", "r561", "r562", "r563", "r564", "r565" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetailss", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r222", "r223", "r306", "r333", "r493", "r494" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementAndLitigationDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.transcodetherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r239", "r360", "r530" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails", "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetailss", "http://www.transcodetherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r239", "r360", "r518", "r519", "r530" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails", "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetailss", "http://www.transcodetherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetailss": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.transcodetherapeutics.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Outstanding payables", "totalLabel": "Total accounts payable and accrued expenses", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails", "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetailss", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentDetails", "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accounts Payable and Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpenses", "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensess" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r6", "r7", "r37" ], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetailss": { "order": 4.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits, Current", "terseLabel": "Payroll and benefits" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails", "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r6", "r7", "r37" ], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetailss": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional and general consulting fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r31", "r79" ], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipmentDetailss": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipmentDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r21", "r364", "r513" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r361", "r362", "r363", "r527", "r528", "r529", "r551" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficit", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r113", "r115", "r145", "r146" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "verboseLabel": "Share based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficit", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r93", "r102", "r109" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Exercise of warrants" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r115", "r139", "r144" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationStockBasedCompensationExpenseDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationStockBasedCompensationExpenseDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r50", "r325", "r416", "r522" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "terseLabel": "Real estate (in sq ft)" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementAndLitigationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r181", "r193", "r219", "r264", "r266", "r268", "r272", "r292", "r293", "r295", "r296", "r297", "r298", "r299", "r301", "r302", "r390", "r394", "r407", "r513", "r541", "r542", "r558" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r3", "r5", "r48", "r219", "r272", "r292", "r293", "r295", "r296", "r297", "r298", "r299", "r301", "r302", "r390", "r394", "r407", "r513", "r541", "r542", "r558" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r116", "r141" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationStockBasedCompensationExpenseDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationStockBasedCompensationExpenseDetailss", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "verboseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalLeasesFutureMinimumSubleaseRentals": { "auth_ref": [ "r201" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Minimum payments receivable in the future under noncancelable subleases.", "label": "Capital Leases, Future Minimum Sublease Rentals", "terseLabel": "Total sublease commitment" } } }, "localname": "CapitalLeasesFutureMinimumSubleaseRentals", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r0", "r28", "r64" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash", "verboseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails", "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r11", "r65" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash", "verboseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r58", "r64", "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, end of period", "periodStartLabel": "Cash, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r58", "r173" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r111", "r114" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityIpoDetails", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetails", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetailss", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsScheduleOfAssumptionsOfFairValueOfWarrantLiabilityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants to purchase number of shares (in shares)", "verboseLabel": "Number of warrants purchased" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityIpoDetails", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetailss", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsScheduleOfAssumptionsOfFairValueOfWarrantLiabilityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r111", "r114" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaboration Agreement" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementAndLitigationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementAndLitigationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r41", "r83", "r186", "r197" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 8)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies." } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r82", "r90", "r290", "r291", "r485" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingencies", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common shares reserved for issuance", "verboseLabel": "Common shares reserved for issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r527", "r528", "r551" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficit", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]" } } }, "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)", "verboseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetsParenthetical", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetsParentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementBalanceSheetsParenthetical", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementBalanceSheetsParenthetical", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r20", "r102" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, share outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementBalanceSheetsParenthetical", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r20", "r513" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock - $0.0001 par value, 290,000,000 shares authorized at December 31, 2021, and 20,000,000 shares authorized at December 31, 2020; 12,904,574 and 4,636,216 shares issued and outstanding at December 31, 2021 and 2020, respectively", "verboseLabel": "Common stock - $0.0001 par value, 290,000,000 shares authorized at September 30, 2022, and December 31, 2021; 12,977,234 and 12,904,574 shares issued and outstanding at September 30, 2022, and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets [Abstract]", "terseLabel": "Deferred tax assets" } } }, "localname": "ComponentsOfDeferredTaxAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r348", "r349", "r350" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred grant income" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureDeferredGrantIncomeDetails", "http://www.transcodetherapeutics.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.", "label": "Contractual Obligation", "terseLabel": "Amount the company has committed to pay" } } }, "localname": "ContractualObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementAndLitigationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInFourthYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation, to be Paid, Year Four", "terseLabel": "Subsequent payments made in fourth anniversary" } } }, "localname": "ContractualObligationDueInFourthYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementAndLitigationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInNextTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation, to be Paid, Year One", "terseLabel": "Subsequent payments made in first anniversary" } } }, "localname": "ContractualObligationDueInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementAndLitigationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInSecondYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation, to be Paid, Year Two", "terseLabel": "Subsequent payments made in second anniversary" } } }, "localname": "ContractualObligationDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementAndLitigationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInThirdYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation, to be Paid, Year Three", "terseLabel": "Subsequent payments made in third anniversary" } } }, "localname": "ContractualObligationDueInThirdYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementAndLitigationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtNoncurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.transcodetherapeutics.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.", "label": "Convertible Debt, Noncurrent", "totalLabel": "Convertible promissory notes, net", "verboseLabel": "Convertible promissory notes, net of debt issuance costs and debt discount" } } }, "localname": "ConvertibleDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "Convertible Debt [Table Text Block]", "terseLabel": "Schedule of convertible promissory notes at the time of IPO comprised" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r66", "r67" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Shares converted (in shares)" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityIpoDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r66", "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Original Debt, Amount", "terseLabel": "Conversion of convertible promissory notes, including embedded derivative, to common stock" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Promissory Notes" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r94", "r217", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r319", "r326", "r327", "r329" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Convertible Promissory Notes" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r15", "r16", "r17", "r182", "r183", "r191", "r225", "r303", "r304", "r305", "r306", "r307", "r309", "r315", "r316", "r317", "r318", "r320", "r321", "r322", "r323", "r324", "r325", "r417", "r501", "r502", "r503", "r504", "r505", "r524" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r17", "r183", "r191", "r330" ], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails": { "order": 1.0, "parentTag": "us-gaap_ConvertibleDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "verboseLabel": "Principal amount of convertible promissory notes" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r175", "r177", "r303", "r417", "r502", "r503" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r39", "r304" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r40", "r225", "r303", "r304", "r305", "r306", "r307", "r309", "r315", "r316", "r317", "r318", "r320", "r321", "r322", "r323", "r324", "r325", "r417", "r501", "r502", "r503", "r504", "r505", "r524" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r40", "r103", "r106", "r107", "r108", "r174", "r175", "r177", "r190", "r225", "r303", "r304", "r305", "r306", "r307", "r309", "r315", "r316", "r317", "r318", "r320", "r321", "r322", "r323", "r324", "r325", "r328", "r417", "r501", "r502", "r503", "r504", "r505", "r524" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": { "auth_ref": [ "r174", "r177" ], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails": { "order": 3.0, "parentTag": "us-gaap_ConvertibleDebtNoncurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.", "label": "Debt Instrument, Unamortized Discount, Noncurrent", "negatedLabel": "Less unamortized debt discounts" } } }, "localname": "DebtInstrumentUnamortizedDiscountNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net [Abstract]", "terseLabel": "Unamortized amounts of debt issuance costs and debt discounts" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges, Policy [Policy Text Block]", "terseLabel": "Deferred Offering Costs" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCosts": { "auth_ref": [ "r14", "r180", "r192" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.", "label": "Deferred Costs, Noncurrent", "terseLabel": "Deferred offering costs" } } }, "localname": "DeferredCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetailss", "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNoncurrentNet": { "auth_ref": [ "r32", "r176" ], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails": { "order": 2.0, "parentTag": "us-gaap_ConvertibleDebtNoncurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Noncurrent, Net", "negatedLabel": "Less unamortized debt issuance costs" } } }, "localname": "DeferredFinanceCostsNoncurrentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeCurrent": { "auth_ref": [ "r540" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Income, Current", "terseLabel": "Deferred grant income", "verboseLabel": "Deferred Grant Income" } } }, "localname": "DeferredIncomeCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureDeferredGrantIncomeDetails", "http://www.transcodetherapeutics.com/role/DisclosureDeferredGrantIncomeDetailss", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredOfferingCosts": { "auth_ref": [ "r47", "r537" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Deferred Offering Costs", "terseLabel": "Deferred offering costs", "verboseLabel": "Deferred offering costs offset" } } }, "localname": "DeferredOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r372" ], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Subtotal deferred tax assets before valuation allowance" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r547" ], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred taxes" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r547" ], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r155", "r548" ], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r155", "r548" ], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r155", "r548" ], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r373" ], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax liability" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r155", "r548" ], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedLabel": "Fixed assets" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetailss": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.", "label": "Deposits Assets, Current", "terseLabel": "Deposits" } } }, "localname": "DepositsAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "http://www.transcodetherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r62", "r77" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r62", "r262" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation expense", "verboseLabel": "Depreciation expenses" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipmentDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r156", "r157", "r158", "r159", "r162", "r224" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivative Liabilities" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "verboseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensation", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensations" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStock": { "auth_ref": [ "r109", "r189" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Common Stock", "terseLabel": "Cash dividends were declared or paid" } } }, "localname": "DividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r33", "r294", "r295", "r296", "r300", "r301", "r302", "r424", "r526" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Due to related parties" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.transcodetherapeutics.com/role/DisclosureRelatedPartyTransactionsDetailss", "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss Per Share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r211", "r231", "r232", "r233", "r234", "r235", "r240", "r242", "r244", "r245", "r246", "r250", "r398", "r399", "r474", "r477", "r496" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share, Basic", "verboseLabel": "Net earnings (loss) per share attributable to common stockholders, basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShareDetails", "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetEarningsLossPerShareDetails", "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations", "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperationss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r211", "r231", "r232", "r233", "r234", "r235", "r242", "r244", "r245", "r246", "r250", "r398", "r399", "r474", "r477", "r496" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net earnings (loss) per share attributable to common stockholders, diluted", "verboseLabel": "Net loss per share, diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShareDetails", "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations", "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperationss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r70", "r72" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Basic and Diluted Earnings (Loss) per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r247", "r248", "r249", "r251" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShare", "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShares" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r220", "r368", "r382" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Federal income tax benefit at statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r545", "r549" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r382", "r545" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "terseLabel": "Deferred true-up" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "auth_ref": [ "r545", "r549" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent", "terseLabel": "Permanent differences" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r545", "r549" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State and local tax, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "auth_ref": [ "r160" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.", "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability", "terseLabel": "Derivative liabilities", "verboseLabel": "Derivative liability" } } }, "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsDetails", "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationStockBasedCompensationExpenseDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationStockBasedCompensationExpenseDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Period for recognition of stock-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationStockBasedCompensationExpenseDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationStockBasedCompensationExpenseDetailss" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r140" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Remaining unrecognized stock-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationStockBasedCompensationExpenseDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationStockBasedCompensationExpenseDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationStockBasedCompensationExpenseDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationStockBasedCompensationExpenseDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r102", "r202", "r207", "r208", "r209", "r226", "r227", "r228", "r230", "r236", "r238", "r252", "r273", "r347", "r361", "r362", "r363", "r378", "r379", "r397", "r408", "r409", "r410", "r411", "r412", "r413", "r480", "r481", "r482", "r491" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficit", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r62", "r95" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of warrant liability", "terseLabel": "Change in fair value of warrant liability", "verboseLabel": "Change in fair market value of warrant liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss", "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations", "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperationss" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetailss", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsScheduleOfAssumptionsOfFairValueOfWarrantLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetailss", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsScheduleOfAssumptionsOfFairValueOfWarrantLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule of assumptions of the fair value of the Company's warrant liability" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsTables", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsTabless" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3FinancialInstrumentsDetails", "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r163", "r171", "r172" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3FinancialInstrumentsDetails", "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r317", "r352", "r353", "r354", "r355", "r356", "r357", "r400", "r433", "r434", "r435", "r502", "r503", "r507", "r508", "r509" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3FinancialInstrumentsDetails", "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurements", "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementss" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r317", "r352", "r353", "r354", "r355", "r356", "r357", "r400", "r435", "r502", "r503", "r507", "r508", "r509" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3FinancialInstrumentsDetails", "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount": { "auth_ref": [ "r165" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount", "terseLabel": "Amount of liability transferred from Level 1 to Level 2" } } }, "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": { "auth_ref": [ "r165" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount", "terseLabel": "Amount of liability transferred from Level 2 to Level 1" } } }, "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r163", "r164" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of fair value measurement within the fair value hierarchy of the Company's financial instruments" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsTables", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsTabless" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r167", "r168" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsTables", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsTabless" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r167", "r168" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of fair value of the warrant liability", "verboseLabel": "Schedule of changes in the fair value of Level 3 financial instruments" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsTables", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsTables", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsTabless" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": { "auth_ref": [ "r404" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3", "terseLabel": "Amount of liability transferred into level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": { "auth_ref": [ "r404" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3", "terseLabel": "Amount of liability transferred out of level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r403" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value", "verboseLabel": "Change in fair value of warrant liability" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3FinancialInstrumentsDetails", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r167" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Fair value, ending balance", "periodStartLabel": "Fair value, beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3FinancialInstrumentsDetails", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r317", "r352", "r353", "r354", "r355", "r356", "r357", "r433", "r434", "r435", "r502", "r503", "r507", "r508", "r509" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsChangesInFairValueOfLevel3FinancialInstrumentsDetails", "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": { "auth_ref": [ "r405" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) recognized in income for derivative asset (liability) after deduction of derivative liability (asset), measured at fair value using unobservable input (level 3) and still held.", "label": "Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r169", "r170" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r270", "r271", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r328", "r344", "r396", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r499", "r532", "r533", "r534", "r567", "r568", "r569", "r570", "r571", "r572", "r573" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetailss", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsScheduleOfAssumptionsOfFairValueOfWarrantLiabilityDetails", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsTables", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsTabless" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "totalLabel": "Total" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyPlantAndEquipmentTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets": { "auth_ref": [ "r522", "r538", "r539" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "terseLabel": "Loss on sale of equipment" } } }, "localname": "GainLossOnDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r62" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on sale of equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r51" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperationss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "verboseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations", "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperationss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrantsReceivableCurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Grants Receivable, Current", "terseLabel": "Grant receivable" } } }, "localname": "GrantsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO", "terseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityIpoDetails", "http://www.transcodetherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.transcodetherapeutics.com/role/DisclosureRelatedPartyTransactionsDetailss", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetails", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STATEMENTS OF OPERATIONS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r284", "r287" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r220", "r369", "r370", "r376", "r380", "r383", "r385", "r386", "r387" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxes", "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxess" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "auth_ref": [ "r546" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.", "label": "Income Tax Examination, Penalties and Interest Accrued", "verboseLabel": "Accrued interest or penalties related to uncertain tax positions" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": { "auth_ref": [ "r546" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.", "label": "Income Tax Examination, Penalties and Interest Expense", "verboseLabel": "Interest or penalties related to uncertain tax positions recognized in the Company's statements of operations" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r221", "r237", "r238", "r263", "r367", "r381", "r384", "r478" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax benefit (expense)", "verboseLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r206", "r365", "r366", "r370", "r371", "r375", "r377" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r495" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred grant income" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "auth_ref": [ "r61" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Due to Related Parties", "verboseLabel": "Payment of amount due to related parties" } } }, "localname": "IncreaseDecreaseInDueToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r61" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Increase (Decrease) in Interest Payable, Net", "terseLabel": "Accrued interest on convertible promissory notes" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r61" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity (Deficit)" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficit", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r176", "r188", "r210", "r261", "r415" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations", "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperationss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r212", "r215", "r216" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r185", "r198" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest Payable", "verboseLabel": "Accrued Interest" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r52", "r260" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "verboseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations", "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperationss" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee Disclosure [Abstract]" } } }, "localname": "LesseeDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend operating lease.", "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "terseLabel": "Option to extend" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r420" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "terseLabel": "Lease commitment", "verboseLabel": "Total lease commitment" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.transcodetherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Terms of agreement" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r36", "r219", "r272", "r292", "r293", "r295", "r296", "r297", "r298", "r299", "r301", "r302", "r391", "r394", "r395", "r407", "r497", "r541", "r558", "r559" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r25", "r184", "r195", "r513", "r525", "r535", "r554" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity (Deficit)", "verboseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r38", "r219", "r272", "r292", "r293", "r295", "r296", "r297", "r298", "r299", "r301", "r302", "r391", "r394", "r395", "r407", "r513", "r541", "r558", "r559" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r8", "r9", "r10", "r17", "r18", "r219", "r272", "r292", "r293", "r295", "r296", "r297", "r298", "r299", "r301", "r302", "r391", "r394", "r395", "r407", "r541", "r558", "r559" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long-term liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term Debt, Other Disclosures [Abstract]" } } }, "localname": "LongTermDebtOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by category of items purchased under a long-term purchase commitment.", "label": "Category of Item Purchased [Axis]" } } }, "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.", "label": "Long-term Purchase Commitment, Category of Item Purchased [Domain]" } } }, "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Long-term Purchase Commitment [Line Items]", "terseLabel": "Research and development" } } }, "localname": "LongTermPurchaseCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.", "label": "Long-term Purchase Commitment [Table]" } } }, "localname": "LongTermPurchaseCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r83", "r84", "r85", "r86", "r87", "r88", "r89", "r91", "r92" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_MajorityShareholderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Owner that controls more than 50 percent of the voting interest in the entity through direct or indirect ownership.", "label": "Major shareholders and co-founders" } } }, "localname": "MajorityShareholderMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.transcodetherapeutics.com/role/DisclosureRelatedPartyTransactionsDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Dividend yield" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetailss", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsScheduleOfAssumptionsOfFairValueOfWarrantLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Expected life (years)" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetailss", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsScheduleOfAssumptionsOfFairValueOfWarrantLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Expected volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetailss", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsScheduleOfAssumptionsOfFairValueOfWarrantLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Risk free interest rate" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetailss", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsScheduleOfAssumptionsOfFairValueOfWarrantLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Fair value per share of Company's common stock" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetailss", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsScheduleOfAssumptionsOfFairValueOfWarrantLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetailss", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsScheduleOfAssumptionsOfFairValueOfWarrantLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetailss", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsScheduleOfAssumptionsOfFairValueOfWarrantLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r254", "r259" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Nature of Business and Liquidity" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidity", "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquiditys" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r214" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r214" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r58", "r60", "r63" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "negatedLabel": "Net cash used in operating activities", "terseLabel": "Net cash used in operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r49", "r63", "r187", "r199", "r203", "r204", "r205", "r209", "r219", "r229", "r231", "r232", "r233", "r234", "r237", "r238", "r243", "r264", "r265", "r267", "r269", "r272", "r292", "r293", "r295", "r296", "r297", "r298", "r299", "r301", "r302", "r399", "r407", "r498", "r541" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperationss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss from operations", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShareDetails", "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetEarningsLossPerShareDetails", "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations", "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperationss", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficit", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Numerator" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShareDetails", "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetEarningsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:", "verboseLabel": "Supplemental disclosure of non-cash investing and financing activities" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r53" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperationss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations", "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperationss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other income (expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations", "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperationss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenseMember": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.", "label": "Operating Expense" } } }, "localname": "OperatingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperationss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations", "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperationss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating Expenses", "verboseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations", "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperationss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r264", "r265", "r267", "r269", "r498" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperationss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations", "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperationss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r555" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Total monthly rent", "verboseLabel": "Operating lease, expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.transcodetherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r153" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "verboseLabel": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nature of Business and Liquidity" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other current assets.", "label": "Other Current Assets [Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "OtherCurrentAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets", "http://www.transcodetherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetss" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r1", "r4", "r536" ], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetailss": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Contract Manufacturers And Research Organizations", "terseLabel": "Contract manufacturers and research organizations" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "http://www.transcodetherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaidInKindInterest": { "auth_ref": [ "r62" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Paid-in-Kind Interest", "terseLabel": "Non-cash interest expense" } } }, "localname": "PaidInKindInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r59" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Payments for Rent", "terseLabel": "Rent payments (per month)" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForUnderwritingExpense": { "auth_ref": [ "r59" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.", "label": "Payments for Underwriting Expense", "terseLabel": "Underwriting commissions" } } }, "localname": "PaymentsForUnderwritingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r55" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r116", "r141" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r19", "r331" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)", "verboseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetsParenthetical", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetsParentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementBalanceSheetsParenthetical", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r19", "r331" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)", "verboseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetsParenthetical", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementBalanceSheetsParenthetical", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r19", "r513" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock - $0.0001 par value; 10,000,000 and 5,000,000 shares authorized at December 31, 2021 and 2020, respectively; -0- shares issued or outstanding at December 31, 2021", "verboseLabel": "Preferred stock - $0.0001 par value; 10,000,000 and 5,000,000 shares authorized at September 30, 2022, and December 31, 2021, respectively; - 0- shares issued and outstanding at September 30, 2022 and December 31, 2021" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r3", "r26", "r27" ], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetailss": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "totalLabel": "Prepaid expenses and other current assets", "verboseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "http://www.transcodetherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetailss", "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r1", "r4", "r282", "r283" ], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetailss": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid operating expenses", "verboseLabel": "Prepaid operating expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "http://www.transcodetherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r2", "r4", "r500", "r536" ], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetailss": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Insurance Premiums", "terseLabel": "Insurance premiums" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "http://www.transcodetherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r57" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from convertible promissory notes", "verboseLabel": "Aggregate principal amount of convertible promissory notes issued during period" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r56" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Net proceeds", "verboseLabel": "Proceeds from initial public offering (IPO) of common stock, net of offering costs" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityIpoDetails", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r56" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Gross proceeds from issuance" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r56" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "terseLabel": "Proceeds from issuance of warrants" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r54" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "verboseLabel": "Proceeds from sale of equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r56", "r142" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r521" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r203", "r204", "r205", "r213", "r219", "r229", "r237", "r238", "r264", "r265", "r267", "r269", "r272", "r292", "r293", "r295", "r296", "r297", "r298", "r299", "r301", "r302", "r389", "r392", "r393", "r399", "r407", "r475", "r498", "r511", "r512", "r520", "r541" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r31", "r80" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyPlantAndEquipmentTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r81", "r486", "r487", "r488" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipment", "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipments" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r30", "r78" ], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipmentDetailss": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Laboratory and computer equipment", "verboseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipmentDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property and Equipment", "verboseLabel": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyPlantAndEquipmentTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r13", "r80", "r196", "r476", "r513" ], "calculation": { "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipmentDetailss": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Fixed assets, net of depreciation", "totalLabel": "Total property and equipment, net", "verboseLabel": "Property and equipment, net of depreciation" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipmentDetailss", "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net, by Type [Abstract]", "verboseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentNetByTypeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r29", "r80", "r486", "r487" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and equipment", "verboseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r12", "r80" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipmentTables", "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipmentTabless" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r12", "r78" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyPlantAndEquipmentTableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "verboseLabel": "Estimated useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyPlantAndEquipmentTableDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock": { "auth_ref": [ "r44" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from owner or affiliate of reporting entity for issuance of shares. Includes, but is not limited to, amount due for award under share-based payment arrangement. Excludes amount due from officer or director.", "label": "Receivable from Shareholders or Affiliates for Issuance of Capital Stock", "negatedLabel": "Subscription receivable" } } }, "localname": "ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesFromStockholderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Category of equity that is due from owners or affiliates of the reporting entity (including due from officers or directors) resulting from the sale of stock before the cash payment is received.", "label": "Subscription Receivable", "terseLabel": "Subscription Receivable" } } }, "localname": "ReceivablesFromStockholderMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficit", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r358", "r423", "r424" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.transcodetherapeutics.com/role/DisclosureRelatedPartyTransactionsDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related party transactions" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.transcodetherapeutics.com/role/DisclosureRelatedPartyTransactionsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related -Party Transactions" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r358", "r423", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r557" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.transcodetherapeutics.com/role/DisclosureRelatedPartyTransactionsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r421", "r422", "r424", "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related -Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureRelatedPartyTransactions", "http://www.transcodetherapeutics.com/role/DisclosureRelatedPartyTransactionss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentArrangementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer.", "label": "Research and Development Arrangement" } } }, "localname": "ResearchAndDevelopmentArrangementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesResearchAndDevelopmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r149", "r200", "r566" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperationss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations", "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperationss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationStockBasedCompensationExpenseDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationStockBasedCompensationExpenseDetailss", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r285", "r286", "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r22", "r109", "r194", "r364", "r483", "r484", "r513" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r202", "r226", "r227", "r228", "r230", "r236", "r238", "r273", "r361", "r362", "r363", "r378", "r379", "r397", "r480", "r482" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficit", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityIpoDetails", "http://www.transcodetherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.transcodetherapeutics.com/role/DisclosureRelatedPartyTransactionsDetailss", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetails", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accounts payable and accrued expenses" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesTables", "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesTabless" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementAndLitigationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of components of deferred tax assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "verboseLabel": "Schedule of computation of basic and diluted net earnings (loss) per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShareTables", "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShareTabless" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of reconciliation of income tax provision (benefit) at effective income tax rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r115", "r138", "r144" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationStockBasedCompensationExpenseDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationStockBasedCompensationExpenseDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r31", "r80" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeOfPropertyAndEquipmentDetails", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyPlantAndEquipmentTableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r178", "r179" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.transcodetherapeutics.com/role/DisclosureRelatedPartyTransactionsDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r116", "r141" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r122", "r130", "r132" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "verboseLabel": "Summary of options activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationTable", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "verboseLabel": "Assumptions for estimating the fair value of options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationTable", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r42", "r99", "r100", "r101", "r103", "r104", "r105", "r106", "r107", "r108", "r109", "r253", "r331", "r332", "r333", "r335", "r339", "r344", "r506", "r517", "r523" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in restricted stock units (RSUs).", "label": "Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]", "terseLabel": "Schedule of unvested restricted common stock" } } }, "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Schedule of computation of diluted earnings (loss) per weighted-average share outstanding" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShareTabless" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r62" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Aggregate amount of severance" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r61" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "verboseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationDetailss" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested restricted common stock, ending balance", "periodStartLabel": "Unvested restricted common stock, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Shares vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetailss" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetailss" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Shares approved for issuance of options or other awards", "verboseLabel": "Shares approved for issuance of options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "verboseLabel": "Options available for future grants" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted average contractual term (years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "verboseLabel": "Options vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "terseLabel": "Forfeited", "verboseLabel": "Number of shares terminated" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetailss" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "netLabel": "Options awarded (in shares)", "terseLabel": "Granted", "verboseLabel": "Options awarded during period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetailss", "http://www.transcodetherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value of the options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetailss" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r141" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Intrinsic value of the outstanding options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetailss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r124", "r141" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, ending balance", "periodStartLabel": "Outstanding, beginning balance", "terseLabel": "Number of options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetailss" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, ending balance", "periodStartLabel": "Outstanding, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetailss" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted average exercise price per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": { "auth_ref": [ "r114", "r141" ], "lang": { "en-us": { "role": { "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased", "verboseLabel": "Exercise price per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Description of terms of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award", "verboseLabel": "Terms of award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r114", "r120" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationStockBasedCompensationExpenseDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationStockBasedCompensationExpenseDetailss", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetailss" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "netLabel": "Exercise price (per share)", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetailss", "http://www.transcodetherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r116", "r121" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Fair value per share of underlying stock" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetailss" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r135", "r143" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationGrantDateFairValueOfOptionsGrantedDetailss" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average contractual term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetailss" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares", "terseLabel": "Shares issuable on exercise of vested options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShareComputationOfDilutedEarningsLossPerWeightedAverageShareOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "verboseLabel": "Exercise price as a percentage of fair value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss" ], "xbrltype": "percentItemType" }, "us-gaap_SharesHeldInEmployeeStockOptionPlanAllocated": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Number of allocated shares held by the Employee Stock Option Plan at balance sheet date. Allocated shares are shares that have been assigned to individual participant accounts based on a known formula.", "label": "Shares Held in Employee Stock Option Plan, Allocated", "terseLabel": "Shares available in ESPP" } } }, "localname": "SharesHeldInEmployeeStockOptionPlanAllocated", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance, end of period (in shares)", "periodStartLabel": "Balance, beginning of period (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficit", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Price per share (in dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityIpoDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent": { "auth_ref": [ "r97" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 }, "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount that is required to be paid, determined under the conditions specified in the contract, if as of the reporting date, the holder of the share has exercised the right to or the shares are mandatorily redeemable after one year from the reporting date or operating cycle, if longer.", "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent", "terseLabel": "Warrant liability" } } }, "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureFairValueMeasurementsDetails", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsScheduleOfAssumptionsOfFairValueOfWarrantLiabilityDetails", "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "monetaryItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State and Local" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r46", "r102", "r202", "r207", "r208", "r209", "r226", "r227", "r228", "r230", "r236", "r238", "r252", "r273", "r347", "r361", "r362", "r363", "r378", "r379", "r397", "r408", "r409", "r410", "r411", "r412", "r413", "r480", "r481", "r482", "r491" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficit", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails", "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetailss", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficit", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r226", "r227", "r228", "r252", "r461" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails", "http://www.transcodetherapeutics.com/role/DisclosureAccountsPayableAndAccruedExpensesDetailss", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficit", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r45", "r102", "r103", "r109", "r320" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficit", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r19", "r20", "r102", "r109" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Shares Issued on ESPP" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r19", "r20", "r102", "r109" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Shares issued (in shares)", "verboseLabel": "Issuance of common stock in initial public offering, net of offering costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityIpoDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficit", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r19", "r20", "r102", "r109", "r126" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Exercised", "verboseLabel": "Exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationAdditionalInformationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetails", "http://www.transcodetherapeutics.com/role/DisclosureShareBasedCompensationInformationAboutOptionsToPurchaseCommonStockDetailss", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficit", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r46", "r102", "r109" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficit", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r19", "r20", "r102", "r109" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock in initial public offering, net of offering costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficit", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r46", "r102", "r109" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r20", "r23", "r24", "r76", "r513", "r525", "r535", "r554" ], "calculation": { "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance, end of period", "periodStartLabel": "Balance, beginning of period", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficit", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity (deficit)", "verboseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementBalanceSheets", "http://www.transcodetherapeutics.com/role/StatementBalanceSheetss" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r112", "r218", "r332", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r345", "r347" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquity", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquitys" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Reverse stock split ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetailss" ], "xbrltype": "pureItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r414", "r428" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.transcodetherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r414", "r428" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r414", "r428" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.transcodetherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r414", "r428" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetailss", "http://www.transcodetherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events." } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r427", "r429" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityIpoDetails", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureConvertiblePromissoryNotesDetails", "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityIpoDetails", "http://www.transcodetherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.transcodetherapeutics.com/role/DisclosureRelatedPartyTransactionsDetailss", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetails", "http://www.transcodetherapeutics.com/role/DisclosureStockholdersEquityDetailss", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetailss", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetails", "http://www.transcodetherapeutics.com/role/StatementStatementsOfStockholdersEquityDeficits" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Initial public offering" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityDetails", "http://www.transcodetherapeutics.com/role/DisclosureNatureOfBusinessAndLiquidityIpoDetails", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetailss" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow", "verboseLabel": "Supplemental disclosure of cash flows" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlows", "http://www.transcodetherapeutics.com/role/StatementStatementsOfCashFlowss" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r270", "r271", "r328", "r344", "r396", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r532", "r533", "r534", "r567", "r568", "r569", "r570", "r571", "r572", "r573" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetailss", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsScheduleOfAssumptionsOfFairValueOfWarrantLiabilityDetails", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsTables", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsTabless" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementAndLitigationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r285", "r286", "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails", "http://www.transcodetherapeutics.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetailss" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r73", "r74", "r75", "r255", "r256", "r257", "r258" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "http://www.transcodetherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciess" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r374" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "verboseLabel": "Change in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants" } } }, "localname": "WarrantsAndRightsNoteDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Assumptions for fair value of warrant liability", "terseLabel": "Assumptions for fair value of warrant liability" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetailss", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsScheduleOfAssumptionsOfFairValueOfWarrantLiabilityDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Underwriter warrants term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetailss", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsScheduleOfAssumptionsOfFairValueOfWarrantLiabilityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember": { "auth_ref": [ "r96", "r98" ], "lang": { "en-us": { "role": { "documentation": "Warrants and rights that embody an unconditional obligation requiring the issuer to redeem the instrument by transferring its assets at a specified or determinable date (or dates) or upon an event certain to occur.", "label": "Warrant liability" } } }, "localname": "WarrantsAndRightsSubjectToMandatoryRedemptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureWarrantsDetailss", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsScheduleOfAssumptionsOfFairValueOfWarrantLiabilityDetails", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsTables", "http://www.transcodetherapeutics.com/role/DisclosureWarrantsTabless" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r241", "r246" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average common shares outstanding, Diluted", "verboseLabel": "Weighted-average common shares outstanding, diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShareDetails", "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations", "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperationss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r240", "r246" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average common shares outstanding, Basic", "verboseLabel": "Weighted-average common shares outstanding, basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShareDetails", "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetEarningsLossPerShareDetails", "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperations", "http://www.transcodetherapeutics.com/role/StatementStatementsOfOperationss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Denominator" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShareDetails", "http://www.transcodetherapeutics.com/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetEarningsLossPerShareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r515": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r516": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.A)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=28183603&loc=d3e692-112598", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r571": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r572": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r573": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262807&loc=d3e22026-110879", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" }